{"id":12796,"date":"2026-02-22T12:46:20","date_gmt":"2026-02-22T12:46:20","guid":{"rendered":"https:\/\/csiag.eu\/?p=12796"},"modified":"2026-03-13T11:56:05","modified_gmt":"2026-03-13T11:56:05","slug":"likums-par-aizsardzibu-pret-masalam","status":"publish","type":"post","link":"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/","title":{"rendered":"Masalu \u201caizsardz\u012bbas\u201c likums?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_86 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Satura r\u0101d\u012bt\u0101js<\/p>\n<span class=\"ez-toc-title-toggle\"><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Was_sind_Masern_%E2%80%93_Spezifische_Evasionsmechanismen\" >Kas ir masalas? - \u012apa\u0161i izvair\u012b\u0161an\u0101s meh\u0101nismi<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Defizitare_Interferon-Antwort_und_NF-%CE%BAB-Dependenz\" >Interferona atbildes reakcijas tr\u016bkums un NF-\u03baB atkar\u012bba<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Dendritische_Zellen_als_primare_Zielzellen_und_Suppression_durch_MeV\" >Dendr\u012bt\u0161\u016bnas k\u0101 prim\u0101r\u0101s m\u0113r\u0137a \u0161\u016bnas un to nom\u0101k\u0161ana ar MeV<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Die_MDA5V-Protein-Interferon-Suppression\" >MDA5\/V prote\u012bna interferona nom\u0101k\u0161ana<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#IL-12-Suppression_und_Th2-Verschiebung\" >IL-12 nom\u0101k\u0161ana un Th2 mai\u0146a<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Gibt_es_pflanzliche_Wirkstoffe_gegen_Masern\" >Vai ir augu izcelsmes akt\u012bv\u0101s vielas pret masal\u0101m?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Was_Huaier_theoretisch_bewirken_kann\" >Ko Huaier teor\u0113tiski var sasniegt<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Wie_ist_der_Ablauf_einer_Masern-Infektion_und_was_bewirken_die_Huaier-Wirkstoffe\" >K\u0101da ir masalu infekcijas gaita un k\u0101 iedarbojas Huaier akt\u012bv\u0101s vielas?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Informationsschreiben_zur_Masern-Impfpflicht_des_MWGFD_eV\" >MWGFD e.V. informat\u012bva v\u0113stule par oblig\u0101to vakcin\u0101ciju pret masal\u0101m.<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#%E2%80%A6_beschneidet_die_Rechte_der_Kinder_und_ihrer_Eltern\" >... ierobe\u017eo b\u0113rnu un vi\u0146u vec\u0101ku ties\u012bbas.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#%E2%80%A6_wie_sie_sich_aus_dem_Masernschutzgesetz_faktisch_ergibt_ist_rechtlich_umstritten\" >... jo tas de facto izriet no Likuma par masalu aizsardz\u012bbu, ir juridiski pretrun\u012bgs.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#%E2%80%A6_ist_medizinisch_sinnlos\" >... ir medic\u012bniski bezj\u0113dz\u012bga<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Rechtsgutachten_%E2%80%93_Ist_die_Impfpflicht_nach_dem_geplanten_Masernschutzgesetz_verfassungswidrig\" >Tiesiskais atzinums \u2013 Vai oblig\u0101t\u0101 vakcin\u0101cija pret masal\u0101m saska\u0146\u0101 ar (pl\u0101noto) Masalu likumu ir antikonstitucion\u0101la?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Betroffene_Grundrechte\" >Skart\u0101s pamatties\u012bbas<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Regelungsmechanismus_und_Zwangsstruktur\" >Regulat\u012bvais meh\u0101nisms un piespiedu strukt\u016bra<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Kritik_an_der_Verhaltnismasigkeit\" >Proporcionalit\u0101tes kritika<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Rechtsstaatliche_und_demokratische_Mangel\" >Tiesiskums un demokr\u0101tijas tr\u016bkumi<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Das_Kombinationsimpfstoff-Problem\" >Kombin\u0113to vakc\u012bnu probl\u0113ma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Fazit\" >Secin\u0101jums<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Entwicklungen_seit_2019\" >Notikumi kop\u0161 2019. gada<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Bundesverfassungsgericht_2022\" >Feder\u0101l\u0101 konstitucion\u0101l\u0101 tiesa (2022)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Das_Kombinationsimpfstoff-Problem_wurde_Realitat\" >Kombin\u0113to vakc\u012bnu probl\u0113ma ir k\u013cuvusi par realit\u0101ti<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#RKI-Bilanz_nach_5_Jahren_2025\" >RKI bilance p\u0113c 5 gadiem (2025. gad\u0101)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Kritische_Nebeneffekte\" >Kritisk\u0101s blakuspar\u0101d\u012bbas<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Ausgeloster_Status\" >Aktiviz\u0113ts statuss<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/#Fazit-2\" >Secin\u0101jums<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Las\u012b\u0161anas laiks<\/span> <span class=\"rt-time\"> 21<\/span> <span class=\"rt-label rt-postfix\">protokols<\/span><\/span>\n<p class=\"wp-block-paragraph\">Pirms m\u0113s non\u0101kam pie <a href=\"https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/Gesetze_und_Verordnungen\/GuV\/M\/Masernschutzgesetz_Kabinett.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Likums par masalu aizsardz\u012bbu<\/a> \u0160aj\u0101 rakst\u0101 m\u0113s vispirms v\u0113lamies sniegt zin\u0101tnisku skaidrojumu par masalu v\u012brusa imunolo\u0123iju Infekciju aizsardz\u012bbas likuma (IfSG) ietvaros.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_sind_Masern_%E2%80%93_Spezifische_Evasionsmechanismen\"><\/span>Kas ir masalas? - \u012apa\u0161i izvair\u012b\u0161an\u0101s meh\u0101nismi<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Defizitare_Interferon-Antwort_und_NF-%CE%BAB-Dependenz\"><\/span>Interferona atbildes reakcijas tr\u016bkums un NF-\u03baB atkar\u012bba<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Galvenais im\u016bndefekts masalu gad\u012bjum\u0101 b\u016btiski at\u0161\u0137iras no klasisk\u0101s v\u012brusu im\u016bn\u0101s atbildes reakcijas:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Masalu v\u012brusa infekcija neizraisa 1. tipa interferonus, bet izraisa citok\u012bnu un hemok\u012bnu veido\u0161anos, kas saist\u012bti ar NF-\u03baB signaliz\u0101ciju un NLRP3 inflam\u0101somas aktiv\u0101ciju, k\u0101 cita starp\u0101 par\u0101d\u012bts \u0161aj\u0101 darb\u0101. <a href=\"https:\/\/www.explorationpub.com\/Journals\/ei\/Article\/1003167\" target=\"_blank\" rel=\"noreferrer noopener\">Izpratne par masalu v\u012brusu: no izol\u0101cijas l\u012bdz imunolo\u0123iskajiem \u0161\u016bnu meh\u0101nismiem un imuniz\u0101cijai 1954-2024<\/a> par\u0101d\u0101s.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u0160\u012b ierobe\u017eot\u0101 atbildes reakcija \u013cauj pla\u0161\u0101kai v\u012brusa replik\u0101cijai un izplat\u012bbai kl\u012bniski klusaj\u0101 latentaj\u0101 f\u0101z\u0113, kas ilgst 10-14 dienas.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dendritische_Zellen_als_primare_Zielzellen_und_Suppression_durch_MeV\"><\/span>Dendr\u012bt\u0161\u016bnas k\u0101 prim\u0101r\u0101s m\u0113r\u0137a \u0161\u016bnas un to nom\u0101k\u0161ana ar MeV<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">MeV infekcija s\u0101kas elpce\u013cu g\u013cot\u0101d\u0101, kur nenobriedu\u0161as plau\u0161u dendr\u012bt\u0161\u016bnas (DC) un\/vai alveol\u0101rie makrof\u0101gi norij vai infic\u0113jas ar MeV da\u013ci\u0146\u0101m un p\u0113c tam migr\u0113 uz limfmezgliem, kur veicina v\u012brusa izplat\u012b\u0161anos. P\u0113t\u012bjums ir pieejams bez maksas piln\u0101 tekst\u0101. <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7994291\/\" target=\"_blank\" rel=\"noreferrer noopener\">Masalu imunit\u0101te un imunosupresija<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">V\u012brusu izvair\u012b\u0161an\u0101s arsen\u0101ls ir \u012bpa\u0161i v\u0113rsts pret DC funkciju: Glikoprote\u012bna H saist\u012b\u0161an\u0101s ar CD150 uz dendr\u012bt\u0161\u016bnu virsmas izraisa IL-12 citok\u012bna, kas nepiecie\u0161ams T \u0161\u016bnu nobrie\u0161anai un prolifer\u0101cijai, k\u0101 ar\u012b DC antig\u0113na prezent\u0101cijai T \u0161\u016bn\u0101m, ra\u017eo\u0161anas inhib\u012bciju.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Die_MDA5V-Protein-Interferon-Suppression\"><\/span>MDA5\/V prote\u012bna interferona nom\u0101k\u0161ana<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Masalu V prote\u012bns m\u0113r\u0137\u0113 uz fosfat\u0101zi PP1 un aiztur to, izmantojot PP1 saisto\u0161o mot\u012bvu C-gal\u0101, ne\u013caujot im\u016bnsensoram MDA5 pild\u012bt savu uzdevumu - br\u012bdin\u0101t, induc\u0113jot citok\u012bnus. P\u0113t\u012bjums, kas diem\u017e\u0113l bez maksas pieejams tikai abstrakta veid\u0101, ir \u0161\u0101ds <a href=\"https:\/\/link.springer.com\/chapter\/10.1007\/978-3-540-70617-5_13\" target=\"_blank\" rel=\"noreferrer noopener\">Masalu v\u012brusa naid\u012bg\u0101 komunik\u0101cija ar saimnieka iek\u0161\u0113jo imunit\u0101ti un dendr\u012bt\u0161\u016bn\u0101m<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">MeV g\u0113nu produkti ir v\u0113rsti pret gandr\u012bz katru IFN indukcijas un IFN signaliz\u0101cijas kask\u0101des posmu, un tikai asto\u0146as v\u012brusu olbaltumvielas veido pretpas\u0101kumu arsen\u0101lu, kas iev\u0113rojami samazina interferona kask\u0101des darb\u012bbu, k\u0101 par\u0101d\u012bts \u0161aj\u0101 p\u0113t\u012bjum\u0101. <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1879625720300109\" target=\"_blank\" rel=\"noreferrer noopener\">Mekl\u0113 un sl\u0113pies: masalu v\u012brusa manipul\u0113jo\u0161\u0101 mijiedarb\u012bba ar iedzimto im\u016bnsist\u0113mu <\/a>- diem\u017e\u0113l pieejams tikai piln\u0101 tekst\u0101 par maksu - skaidri pier\u0101d\u012bts.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"IL-12-Suppression_und_Th2-Verschiebung\"><\/span>IL-12 nom\u0101k\u0161ana un Th2 mai\u0146a<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">IL-12 sekr\u0113cijas visp\u0101r\u0113ja inhib\u012bcija nov\u0113r\u0161 Th1 \u0161\u016bnu popul\u0101cijas indukciju un veicina Th2 \u0161\u016bnu nobrie\u0161anu ar pretiekaisuma \u012bpa\u0161\u012bb\u0101m. Tas ir b\u016btisks im\u016bnsupresijas meh\u0101nisms.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gibt_es_pflanzliche_Wirkstoffe_gegen_Masern\"><\/span>Vai ir augu izcelsmes akt\u012bv\u0101s vielas pret masal\u0101m?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>N\u0113, augu izcelsmes vielas nevar blo\u0137\u0113t \u0161o meh\u0101nismu t\u0101pat k\u0101 sint\u0113tiskie pept\u012bdi vai antivielas.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ja b\u016btu l\u012bdzeklis, kas var\u0113tu uztur\u0113t p38 fosforil\u0113\u0161anu, neraugoties uz MeV inhib\u012bciju, piem\u0113ram, aktiviz\u0113jot aug\u0161up\u0113j\u0101s kin\u0101zes, piem\u0113ram, TAK1, IL-12 veido\u0161anos var\u0113tu da\u013c\u0113ji atjaunot. \u0160im a\u0123entam b\u016btu j\u0101rodas dendr\u012bt\u0161\u016bn\u0101s.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>p38 Aktiviz\u0113t MAPK (neaktiviz\u0113t)<\/li>\n\n\n\n<li>\u012apa\u0161i stimul\u0113 TAK1<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Un \u0161\u0101da akt\u012bv\u0101 viela nav zin\u0101ma.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Masalu im\u016bnsupresija ir ne tikai visp\u0101r\u0113js iekaisuma defekts, bet ar\u012b <strong>\u013boti specifiska v\u012brusu nolaup\u012b\u0161anas strat\u0113\u0123ija<\/strong>, ko ir gr\u016bti vai pat neiesp\u0113jami apkarot ar univers\u0101liem bot\u0101niskajiem l\u012bdzek\u013ciem.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">V\u012brusu izvair\u012b\u0161an\u0101s arsen\u0101ls ir \u012bpa\u0161i v\u0113rsts pret DC funkciju: Glikoprote\u012bna H saist\u012b\u0161an\u0101s ar CD150 uz dendr\u012bt\u0161\u016bnu virsmas izraisa IL-12 citok\u012bna, kas nepiecie\u0161ams T \u0161\u016bnu nobrie\u0161anai un prolifer\u0101cijai, k\u0101 ar\u012b DC antig\u0113na prezent\u0101cijai T \u0161\u016bn\u0101m, ra\u017eo\u0161anas inhib\u012bciju.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Un \u0161o meh\u0101nismu pa\u0161laik var izmantot tikai<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Monoklon\u0101l\u0101s antivielas pret SLAM<\/strong> <\/li>\n\n\n\n<li><strong>MeV-HSint\u0113tiskie pept\u012bdi<\/strong> (piem\u0113ram, SGFDPLITHA) <\/li>\n\n\n\n<li><strong>V\u012brusu neitraliz\u0113jo\u0161as antivielas<\/strong> (t\u0101pat k\u0101 ar masalu vakc\u012bnu).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">tiek blo\u0137\u0113ts.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_Huaier_theoretisch_bewirken_kann\"><\/span>Ko Huaier teor\u0113tiski var sasniegt<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ja Huaier izrais\u012btu apm\u0101c\u012btu imunit\u0101ti, teor\u0113tiski var\u0113tu<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>stiprina s\u0101kotn\u0113jo iedzimto im\u016bnsist\u0113mas reakciju elpce\u013cu g\u013cot\u0101d\u0101.<\/li>\n\n\n\n<li>samazina v\u012brusa replik\u0101ciju pirmaj\u0101s 1-2 dien\u0101s.<\/li>\n\n\n\n<li>samazin\u0101t v\u012brusa daudzumu, pirms v\u012bruss sasniedz limfmezglus.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">bet <strong>ne<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>nov\u0113rst IL-12 nom\u0101k\u0161anu dendr\u012bt\u0161\u016bn\u0101s ar MeV-H prote\u012bnu.<\/li>\n\n\n\n<li>nov\u0113rst SLAM lejupsl\u012bdi.<\/li>\n\n\n\n<li>Th1\u2192Th2 mai\u0146as atcel\u0161ana<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wie_ist_der_Ablauf_einer_Masern-Infektion_und_was_bewirken_die_Huaier-Wirkstoffe\"><\/span>K\u0101da ir masalu infekcijas gaita un k\u0101 iedarbojas Huaier akt\u012bv\u0101s vielas?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Huaier galvenok\u0101rt str\u0101d\u0101 <strong>1-3 posms<\/strong>, lai veicin\u0101tu agr\u012bnu im\u016bnsist\u0113mas aktiviz\u0101ciju un pretv\u012brusu citok\u012bnu atbildes reakciju. <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PRR aktiviz\u0113\u0161ana (1. f\u0101ze)<\/strong><br>agr\u012bna noteik\u0161ana, piem\u0113ram, TLR, RIG-I, MDA5.<\/li>\n\n\n\n<li><strong>Kin\u0101\u017eu aktiviz\u0101cija un NF-\u03baB \/ MAPK \/ PI3K-AKT (2. f\u0101ze)<\/strong><br>Sign\u0101lu pastiprin\u0101\u0161ana, iekaisuma reakcija, \u0161\u016bnu izdz\u012bvo\u0161ana<\/li>\n\n\n\n<li><strong>Transkripcijas programmas un citok\u012bni (3. f\u0101ze)<\/strong><br>IFN-\u03b1\/\u03b2, TNF-\u03b1, IL-6, IL-1\u03b2 veido\u0161an\u0101s<\/li>\n\n\n\n<li><strong>Paral\u0113li sign\u0101la ce\u013ci<\/strong><br>MAPK kask\u0101de (RAS \u2192 RAF \u2192 MEK \u2192 ERK \u2192 AP-1)<br>PI3K \u2192 AKT \u2192 mTOR \u2192 Metabolisms\/\u0161\u016bnu izdz\u012bvo\u0161ana<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>4. un 5. posms<\/strong> (interferona signaliz\u0101cija, pretv\u012brusu iedarb\u012bbas f\u0101ze) tiek netie\u0161i atbalst\u012bta, iesp\u0113jams, pastiprinot ISG transkripciju:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Liel\u0101ka IFN-\u03b1\/\u03b2 veido\u0161an\u0101s 3. f\u0101z\u0113<\/strong><br>- Huaier palielina NF-\u03baB un IRF3 \u2192 rodas vair\u0101k IFN-\u03b1\/\u03b2.<br>- P\u0113c tam \u0161is IFN iedarbojas uz IFNAR1\/2 4. f\u0101z\u0113 \u2192 sp\u0113c\u012bg\u0101ka JAK-STAT aktiv\u0101cija \u2192 ISGF3 kompleksa veido\u0161an\u0101s.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sign\u0101la pastiprin\u0101\u0161ana caur PI3K-AKT<\/strong><br>- Huaier aktiviz\u0113 PI3K-AKT 2. f\u0101z\u0113, kas, k\u0101 zin\u0101ms, palielina JAK-STAT signaliz\u0101cijas un transkripcijas faktoru efektivit\u0101ti.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lab\u0101ka \u0161\u016bnu gatav\u012bba transkripcijai<\/strong><br>- Paral\u0113li procesi, piem\u0113ram, MAPK signaliz\u0113\u0161ana un epigen\u0113tisk\u0101 modul\u0101cija (HAT, HDAC, DNMT), var\u0113tu padar\u012bt hromat\u012bna strukt\u016bru labv\u0113l\u012bg\u0101ku ISG transkripcijai.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Lai lab\u0101k izprastu Hauaiera polisahar\u012bdu un masalu v\u012brusa 5 f\u0101zes un signaliz\u0101cijas ce\u013cus, turpm\u0101k att\u0113lots att\u0113ls:<\/p>\n\n\n\n<ol class=\"wp-block-list\"><\/ol>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/csiag.eu\/wp-content\/uploads\/2026\/02\/Masern_Huaier_V4-1024x683.png\" alt=\"\" class=\"wp-image-12870\" srcset=\"https:\/\/csiag.eu\/wp-content\/uploads\/2026\/02\/Masern_Huaier_V4-1024x683.png 1024w, https:\/\/csiag.eu\/wp-content\/uploads\/2026\/02\/Masern_Huaier_V4-300x200.png 300w, https:\/\/csiag.eu\/wp-content\/uploads\/2026\/02\/Masern_Huaier_V4-768x512.png 768w, https:\/\/csiag.eu\/wp-content\/uploads\/2026\/02\/Masern_Huaier_V4-18x12.png 18w, https:\/\/csiag.eu\/wp-content\/uploads\/2026\/02\/Masern_Huaier_V4-930x620.png 930w, https:\/\/csiag.eu\/wp-content\/uploads\/2026\/02\/Masern_Huaier_V4.png 1536w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Informationsschreiben_zur_Masern-Impfpflicht_des_MWGFD_eV\"><\/span>MWGFD e.V. informat\u012bva v\u0113stule par oblig\u0101to vakcin\u0101ciju pret masal\u0101m.<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Turpm\u0101k ir reproduc\u0113ts saturs ar laipnu at\u013cauju (dat\u0113ts ar 2026. gada 12. martu). <a href=\"https:\/\/meine-freie-impfentscheidung.de\/media\/download\/broschuere_a4_doppelseitig.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Publik\u0101cija<\/a> MWGFD e.V. (<em>\u0100rsti un zin\u0101tnieki par vesel\u012bbu, br\u012bv\u012bbu un demokr\u0101tiju e.V.<\/em>) ar tekst\u0101 k\u0101 atsauces iek\u013caut\u0101m un\/vai papildin\u0101t\u0101m sait\u0113m.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Likums par masalu aizsardz\u012bbu de facto noved pie oblig\u0101tas vakcin\u0101cijas un p\u0101rk\u0101pj medic\u012bnas \u0113tiku.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Diez vai ir k\u0101da jut\u012bg\u0101ka mijiedarb\u012bba par \u0101rsta un pacienta mijiedarb\u012bbu. Pacients psiholo\u0123iski un bie\u017ei vien ar\u012b fiziski ir neaizsarg\u0101t\u0101 st\u0101vokl\u012b. Vi\u0146\u0161 ir ar\u012b v\u0101j\u0101k\u0101 poz\u012bcij\u0101 zin\u0101\u0161anu, atkar\u012bbas un statusa zi\u0146\u0101.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Labv\u0113l\u012bga \u0101rsta un pacienta mijiedarb\u012bba var notikt tikai tad, ja past\u0101v piln\u012bga uztic\u0113\u0161an\u0101s.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u0160\u012b iemesla d\u0113\u013c \u0161\u012bs mijiedarb\u012bbas \u0113tiskie standarti jau senos laikos tika kodific\u0113ti tekst\u0101, kas mums ir paz\u012bstams k\u0101 \u201e<em>Hipokr\u0101ta zv\u0113rests<\/em>\u201c ir zin\u0101ms. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Svar\u012bg\u0101ko principu, kas no t\u0101 izriet, var apkopot ar formulu \u201e<em>primum nil nocere<\/em>\u201c, kas noz\u012bm\u0113 \u201epirmk\u0101rt, nekait\u0113\u201c. 20. gadsimt\u0101, ko raksturoja \u013caunpr\u0101t\u012bga medic\u012bnas izmanto\u0161ana nacistu vald\u012b\u0161anas laik\u0101 un jap\u0101\u0146u okup\u0101cijas laik\u0101 \u0136\u012bn\u0101 un citur, otrs \u0113tikas st\u016brakmens bija \u0113tiskais princips. <em>Inform\u0113tas piekri\u0161anas princips<\/em> pievienots.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u0160o \u0113tisko principu uzdevums ir pacienta labkl\u0101j\u012bbu izvirz\u012bt visu apsv\u0113rumu centr\u0101, br\u012bvi balstoties uz Ciceronu: \u201e...\u201e<em>salus aegroti suprema lex<\/em>\u201c - pacienta labkl\u0101j\u012bba ir augst\u0101kais likums.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pieprasot pier\u0101d\u012bjumu par vakcin\u0101ciju pret masal\u0101m, Masalu aizsardz\u012bbas likums de facto noved pie oblig\u0101tas vakcin\u0101cijas pret masal\u0101m un t\u0101d\u0113j\u0101di lo\u0123iski p\u0101rk\u0101pj inform\u0113tas piekri\u0161anas pamatprincipu, jo: P\u0113c defin\u012bcijas no oblig\u0101ta pas\u0101kuma nevar atteikties, un t\u0101p\u0113c piekri\u0161ana nav b\u016btiska.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Princips nenodar\u012bt kait\u0113jumu bie\u017ei tiek p\u0101rprasts. Tas nenoz\u012bm\u0113, ka profilakses nol\u016bkos ir j\u0101aizliedz visas iesp\u0113jam\u0101s briesmas, bet gan to, ka \u0101rst\u0113\u0161ana ir j\u0101piem\u0113ro tikai tad, ja ir p\u0101rliec\u012bba, ka konkr\u0113taj\u0101 gad\u012bjum\u0101 t\u0101, visticam\u0101k, dos liel\u0101ku labumu nek\u0101 kait\u0113jumu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Faktiskais pien\u0101kums vakcin\u0113ties pret masal\u0101m, kas izriet no Aizsardz\u012bbas pret masal\u0101m likuma, ir nep\u0101rprotams \u0161\u0101 principa p\u0101rk\u0101pums, jo vakcin\u0101cija sniedz tikai teor\u0113tisku labumu attiec\u012bgajai personai, bet noteikti rada izm\u0113r\u0101mu risku blakuspar\u0101d\u012bbu d\u0113\u013c.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%E2%80%A6_beschneidet_die_Rechte_der_Kinder_und_ihrer_Eltern\"><\/span>... ierobe\u017eo b\u0113rnu un vi\u0146u vec\u0101ku ties\u012bbas.<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Kop\u0161 2020. gada marta sp\u0113k\u0101 eso\u0161aj\u0101 \u201eAizsardz\u012bbas pret masal\u0101m likum\u0101\u201c ir iek\u013cauts de facto vakcin\u0101cijas pien\u0101kums, kas liek vec\u0101kiem savus b\u0113rnus vakcin\u0113t pret masal\u0101m, jo \u012bpa\u0161i, ja vi\u0146i v\u0113las vi\u0146us laist dienas apr\u016bpes centr\u0101 vai b\u0113rnud\u0101rz\u0101.<br>Tas attiecas ar\u012b uz skol\u0113niem p\u0113c 9. m\u0101c\u012bbu gada.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Vec\u0101kiem, kuri p\u0101rk\u0101pj \u0161o pien\u0101kumu sniegt pier\u0101d\u012bjumus, bie\u017ei vien ir uzlikti lieli naudas sodi. Faktiskais vakcin\u0101cijas pien\u0101kums, kas saist\u012bts ar Likumu par masalu aizsardz\u012bbu, ir rupj\u0161 svar\u012bgu pamatties\u012bbu p\u0101rk\u0101pums, piem\u0113ram, m\u016bsu ties\u012bbu uz v\u0101rda br\u012bv\u012bbu. <em><a href=\"https:\/\/www.gesetze-im-internet.de\/gg\/art_2.html\" target=\"_blank\" rel=\"noopener\">2. pants GG<\/a><\/em> ties\u012bbas uz fizisko neaizskaram\u012bbu un ties\u012bbas br\u012bvi p\u0101rvietoties, ko garant\u0113 <em>6. pants GG<\/em> raksturo k\u0101 \u201evec\u0101ku ties\u012bbas\u201c, piem\u0113ram. <a href=\"https:\/\/individuelle-impfentscheidung.de\/fileadmin\/Downloads\/Rechtsgutachten_Rixen_Langfassung.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Juridiskais atzinums<\/a> universit\u0101tes profesors Dr. Stephan Rixen no 2019. gada 11. oktobra (118. lpp.):<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201e<em><strong>(Pl\u0101not\u0101) Masalu aizsardz\u012bbas likuma noteikumi par oblig\u0101to vakcin\u0101ciju p\u0101rk\u0101pj \u0101rstu pamatties\u012bbas, kas noteiktas Pamatlikuma 12. panta 1. punkt\u0101 un 3. panta 1. punkt\u0101.<\/strong><\/em>\u201e,<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">un V\u0101cijas Civilkodekss (<em><a href=\"https:\/\/www.gesetze-im-internet.de\/bgb\/__1626.html\" target=\"_blank\" rel=\"noreferrer noopener\">BGB 1626. PANTS<\/a><\/em>) par vec\u0101ku ties\u012bb\u0101m uz aizg\u0101d\u012bbu p\u0101r saviem b\u0113rniem:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201e<em>(1) <strong>Vec\u0101kiem ir pien\u0101kums un ties\u012bbas r\u016bp\u0113ties par nepilngad\u012bgo b\u0113rnu (vec\u0101ku aizg\u0101d\u012bba). Vec\u0101ku apr\u016bpe ietver b\u0113rna personisk\u0101s apr\u016bpes (personisk\u0101 apr\u016bpe) un b\u0113rna mantas apr\u016bpes (mantas apr\u016bpe) pien\u0101kumus.<\/strong>.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>(2) <strong>Vec\u0101ki sav\u0101 apr\u016bp\u0113 un audzin\u0101\u0161an\u0101 \u0146em v\u0113r\u0101 b\u0113rna augo\u0161\u0101s sp\u0113jas un pieaugo\u0161o vajadz\u012bbu r\u012bkoties patst\u0101v\u012bgi un atbild\u012bgi. Vi\u0146i p\u0101rrun\u0101 ar b\u0113rnu vec\u0101ku apr\u016bpes jaut\u0101jumus, ja tas ir lietder\u012bgi atbilsto\u0161i b\u0113rna att\u012bst\u012bbas pak\u0101pei, un cen\u0161as pan\u0101kt vieno\u0161anos.<\/strong><\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>(3) <strong>Sazi\u0146a ar abiem vec\u0101kiem parasti ir b\u0113rna interes\u0113s. Tas pats attiecas uz saskarsmi ar cit\u0101m person\u0101m, ar kur\u0101m b\u0113rnam ir saikne, ja t\u0101s uztur\u0113\u0161ana ir labv\u0113l\u012bga b\u0113rna att\u012bst\u012bbai.<\/strong>\u201e<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Saska\u0146\u0101 ar <a href=\"https:\/\/www.gesetze-im-internet.de\/gg\/art_6.html\" target=\"_blank\" rel=\"noreferrer noopener\"><em>GG 6. panta 2. punkta 1. teikums<\/em> <\/a>Tom\u0113r valsts nedr\u012bkst iejaukties vec\u0101ku ties\u012bb\u0101s audzin\u0101t savus b\u0113rnus bez attaisnojo\u0161a iemesla:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201e<em><strong>B\u0113rnu apr\u016bpe un audzin\u0101\u0161ana ir vec\u0101ku dabisk\u0101s ties\u012bbas un vi\u0146u galvenais pien\u0101kums.<\/strong>.<\/em>\u201e<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Feder\u0101l\u0101s Konstitucion\u0101l\u0101s tiesas 2022. gada 21. j\u016blija l\u0113mums par oblig\u0101to vakcin\u0101ciju pret masal\u0101m (<em><a href=\"https:\/\/www.bundesverfassungsgericht.de\/SharedDocs\/Entscheidungen\/DE\/2020\/05\/rk20200511_1bvr046920.html\" target=\"_blank\" rel=\"noreferrer noopener\">1 BvR 469\/20, 1 BvR 471\/20, 1 BvR470\/20, 1 BvR 472\/20<\/a><\/em>) nav pier\u0101d\u012bjis, ka vakcin\u0101cija pret masal\u0101m ir \u0161\u0101ds iemesls.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">V\u0113l pirms sprieduma pasludin\u0101\u0161anas tiesne\u0161i paredz\u0113ja, ka vec\u0101ki \u201e<em>Vesel\u012bbas apr\u016bpe<\/em>\u201c \u201e<em>ir maz\u0101k br\u012bvas, lai p\u0101rk\u0101ptu medic\u012bnisk\u0101s pamatot\u012bbas standartus.<\/em>\".<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">T\u0101p\u0113c tiesa uzskat\u012bja, ka vakcin\u0101cija bija \u201emedic\u012bniski pamatota\u201c jau no pa\u0161a s\u0101kuma, t. i., v\u0113l pirms p\u0101rbaudes, lai gan tie\u0161i to tiesai bija j\u0101p\u0101rbauda.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Paskaidrojuma rakst\u0101 ir iek\u013cauti daudzi apgalvojumi2 , kas no medic\u012bnisk\u0101 un zin\u0101tnisk\u0101 viedok\u013ca ir nepamatoti, piem\u0113ram, ka.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li> \"<em>Vakcin\u0101cija pret masal\u0101m nodro\u0161ina dro\u0161u aizsardz\u012bbu pret ak\u016bt\u0101m masal\u0101m.<\/em><\/li>\n\n\n\n<li><em>Vakcin\u0101cija izraisa im\u016bnreakciju, kas ir sal\u012bdzin\u0101ma ar dabisk\u0101s infekcijas reakciju.<\/em>\"<\/li>\n\n\n\n<li>\"<em>P\u0113c veiksm\u012bgas imuniz\u0101cijas ar dz\u012bvu vakc\u012bnu tiek nodro\u0161in\u0101ta m\u016b\u017ea aizsardz\u012bba pret masal\u0101m.<\/em>\"<\/li>\n\n\n\n<li>\"<em>Vakcin\u0101cijas efektivit\u0101te, vakcin\u0101cijas reakcijas un vakcin\u0101cijas komplik\u0101cijas ir zin\u0101tniski labi izp\u0113t\u012btas.<\/em>\"<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Visas \u0161\u012bs t\u0113zes ir atsp\u0113kotas pa\u0161reiz\u0113j\u0101 Cochrane p\u0101rskat\u0101 un Eiropas Slim\u012bbu profilakses un kontroles centra (ECDC) gada zi\u0146ojum\u0101 iek\u013cautajos epidemiolo\u0123iskajos datos:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD004407.pub5\/full\" target=\"_blank\" rel=\"noreferrer noopener\">Pietrantonj et al: Vakc\u012bnas pret masal\u0101m, masali\u0146\u0101m, masali\u0146\u0101m un masali\u0146\u0101m b\u0113rniem. Cochrane 2021<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.ecdc.europa.eu\/en\/publications-data\/measles-annual-epidemiological-report-2024\" target=\"_blank\" rel=\"noreferrer noopener\">ECDC: Masalu gada epidemiolo\u0123iskais zi\u0146ojums 2024. gad\u0101<\/a><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Vakcin\u0101cija pret masal\u0101m nenodro\u0161ina dro\u0161u aizsardz\u012bbu (tikai 80-85% tie\u0161a kontakta gad\u012bjum\u0101 ar slimu cilv\u0113ku).<\/li>\n\n\n\n<li>Im\u016bnreakcija p\u0113c vakcin\u0101cijas ir zem\u0101ka par imunit\u0101ti dabiskas infekcijas rezult\u0101t\u0101.<\/li>\n\n\n\n<li>Jau t\u0101 ierobe\u017eot\u0101 aizsardz\u012bba laika gait\u0101 izs\u012bkst.<\/li>\n\n\n\n<li>Vakcin\u0101cijas efektivit\u0101te un dro\u0161\u012bba nav pietiekami izp\u0113t\u012bta. Cochrane p\u0101rskata autori<br>savus apgalvojumus cita starp\u0101 pamato ar nov\u0113rojumu p\u0113t\u012bjumiem, no kuriem da\u017ei ir zem\u0101kas kvalit\u0101tes, un nov\u0113rt\u0113.<br>pier\u0101d\u012bjumus v\u0113rt\u0113 k\u0101 zemas vai vid\u0113jas pak\u0101pes.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Ar\u012b apgalvojumi par subak\u016btu skleroz\u0113jo\u0161u panencefal\u012btu (SSPE) k\u0101 iesp\u0113jam\u0101m v\u0113l\u012bn\u0101m masalu sek\u0101m zin\u0101tniski ir vair\u0101k nek\u0101 ap\u0161aub\u0101mi. Un, pamatoti atsaucoties uz paaugstin\u0101tu masalu komplik\u0101ciju skaitu z\u012bdai\u0146u vecum\u0101 vai pirmaj\u0101 dz\u012bves gad\u0101, Feder\u0101l\u0101 konstitucion\u0101l\u0101 tiesa ac\u012bmredzami ir ignor\u0113jusi faktu, ka vakcin\u0113to m\u0101\u0161u v\u0101j\u0101s vai visp\u0101r neeso\u0161\u0101s ligzdi\u0146u aizsardz\u012bbas d\u0113\u013c masalas kop\u0161 vakcin\u0101cijas ievie\u0161anas ir k\u013cuvu\u0161as izplat\u012bt\u0101kas tikai z\u012bdai\u0146iem.<br>T\u0101d\u0113\u013c Feder\u0101l\u0101 Konstitucion\u0101l\u0101 tiesa ir neizb\u0113gami j\u0101p\u0101rskata \u0161is l\u0113mums.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%E2%80%A6_wie_sie_sich_aus_dem_Masernschutzgesetz_faktisch_ergibt_ist_rechtlich_umstritten\"><\/span>... jo tas de facto izriet no Likuma par masalu aizsardz\u012bbu, ir juridiski pretrun\u012bgs.<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Likums par masalu aizsardz\u012bbu apdraud ar\u012b m\u016bsu pa\u0161noteik\u0161anos un pa\u0161atbild\u012bgu vesel\u012bbu, jo tas ir \u201eTrojas zirgs\u201c, kas nodro\u0161ina jaunu vakcin\u0101cijas pien\u0101kumu pl\u0101nu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Piem\u0113ram, Pasaules Vesel\u012bbas organiz\u0101cija var\u0113tu klasific\u0113t turpm\u0101kus \u201ejaunus\u201c patog\u0113nus k\u0101 pand\u0113mijai b\u016btiskus, ko veicin\u0101s V\u0101cijas vald\u012bbas 2025. gada septembr\u012b pie\u0146emtie PVO Starptautisko vesel\u012bbas aizsardz\u012bbas noteikumu groz\u012bjumi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Arguments, kas tika izvirz\u012bts par labu Likuma par aizsardz\u012bbu pret masal\u0101m ievie\u0161anai un taj\u0101 paredz\u0113tajai de facto oblig\u0101tajai vakcin\u0101cijai, bija apgalvotais samazin\u0101jums v\u0113lm\u0113 vakcin\u0113ties.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u0160is arguments ir k\u013c\u016bdains. Taj\u0101 laik\u0101 97 % b\u0113rnu bija vakcin\u0113ti vismaz vienu reizi un 93 % - divas reizes. \u0160ie skait\u013ci p\u0113d\u0113jo gadu laik\u0101 ir maz main\u012bju\u0161ies. Tas noz\u012bm\u0113, ka V\u0101cij\u0101 vakcin\u0101cijas p\u0101rkl\u0101jums bija iev\u0113rojami augst\u0101ks nek\u0101 cit\u0101s valst\u012bs, kur\u0101s jau bija ieviesta vakcin\u0101cijas programma.<br>vakcin\u0101cija bija oblig\u0101ta.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.rki.de\/DE\/Aktuelles\/Publikationen\/Epidemiologisches-Bulletin\/2019\/18_19.pdf?__blob=publicationFile&amp;v=1\" target=\"_blank\" rel=\"noreferrer noopener\">(5)<\/a> \u201e<strong><em>Pirm\u0101s vakcin\u0101cijas pret masal\u0101m vakcin\u0101cijas l\u012bmenis pieauga no 95,9 % (2008. gad\u0101) l\u012bdz 96,7 % (2012. gad\u0101) un 2017. gad\u0101 sasniedza 97,1 % vis\u0101 valst\u012b (t\u0101pat k\u0101 2016. gad\u0101) (sk. 1. att\u0113lu, 148. lpp.).<\/em><\/strong>\u201e<br>\u201eI<strong><em>n 2017. gad\u0101 92,6 % b\u0113rnu divas reizes tika p\u0101rbaud\u012bti uz epid\u0113misko parot\u012btu un c\u016bci\u0146\u0101m, uzs\u0101kot m\u0101c\u012bbas skol\u0101.<br>vakcin\u0113ti pret masali\u0146\u0101m.<\/em><\/strong>\u201e<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/edoc.rki.de\/bitstream\/handle\/176904\/11635\/EB-15-2024-BEITRAG-Masern.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">(6)<\/a> \u201e<strong><em>Piem\u0113ram, 97,2% no b\u0113rniem 2020. gada skolas gaitu uzs\u0101k\u0161anas p\u0101rbaud\u0113s (diapazons feder\u0101l\u0101s zemes l\u012bmen\u012b: 95,3%-98,6%) bija sa\u0146\u0113mu\u0161i pirmo vakc\u012bnas devu un 92,7% (diapazons feder\u0101l\u0101s zemes l\u012bmen\u012b: 85,0%-95,8%) - ar\u012b otro vakc\u012bnas devu.<\/em><\/strong>\u201e<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ar\u012b \u201emasalu izskau\u0161ana\u201c, kas saska\u0146\u0101 ar ties\u012bbu akta tekstu ir m\u0113r\u0137is, ir tikai aizsegs. Da\u017e\u0101d\u0101s iest\u0101d\u0113s at\u0161\u0137iras pat izskau\u0161anas defin\u012bcija. T\u0101 saukt\u0101 \u201eNacion\u0101l\u0101 masalu\/marcelozes verifik\u0101cijas komisija\u201c (NAVKO) run\u0101 par r\u0101d\u012bt\u0101ju &lt;1 saslim\u0161anas gad\u012bjums uz 1 miljonu iedz\u012bvot\u0101ju. 7<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.rki.de\/DE\/Themen\/Infektionskrankheiten\/Impfen\/Eliminationsprogramme\/Nationale-Verifizierungskommission-Masern-Roeteln\/Berichte\/Bericht_2023.pdf?__blob=publicationFile&amp;v=4\" target=\"_blank\" rel=\"noreferrer noopener\">(7)<\/a> \u201e... <em><strong>2023. gad\u0101 saska\u0146\u0101 ar atsauces defin\u012bciju tika re\u0123istr\u0113ti 79 saslim\u0161anas gad\u012bjumi (saslimst\u012bba 0,9 uz 1 miljonu iedz\u012bvot\u0101ju).<\/strong><\/em> ....\u201c<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In the <a href=\"https:\/\/www.rki.de\/DE\/Themen\/Infektionskrankheiten\/Impfen\/Eliminationsprogramme\/Nationale-Verifizierungskommission-Masern-Roeteln\/Berichte\/Bericht_2024.pdf?__blob=publicationFile&amp;v=3\" target=\"_blank\" rel=\"noreferrer noopener\">Publik\u0101cija 2024. gadam<\/a> taj\u0101 ir teikts:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201e... <strong><em>2024. gad\u0101 saska\u0146\u0101 ar atsauces defin\u012bciju tika re\u0123istr\u0113ti 645 saslim\u0161anas gad\u012bjumi (saslimst\u012bba 7,6 uz 1 miljonu iedz\u012bvot\u0101ju).<\/em><\/strong> ...\u201c<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tom\u0113r vair\u0101ki starptautiski p\u0113t\u012bjumi liecina, ka piln\u012bga masalu izskau\u0161ana nav iesp\u0113jama,<br>pat ne ar vakcin\u0101ciju. Masalu uzliesmojumus nevar\u0113ja nov\u0113rst ar augstu imuniz\u0101cijas l\u012bmeni.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/academic.oup.com\/trstmh\/article-abstract\/91\/6\/716\/1937272?redirectedFrom=fulltext&amp;login=false\" target=\"_blank\" rel=\"noreferrer noopener\">(9)<\/a> \u201e<em><strong>\u0160is p\u0113t\u012bjums apstiprin\u0101ja nov\u0113rojumu, ka revakcin\u0101cija veiksm\u012bgi izraisa antivielu atbildes reakciju b\u0113rniem ar zemu vai nenosak\u0101mu titru pirms revakcin\u0101cijas, bet tas ar\u012b apstiprin\u0101ja, ka vakc\u012bnas izrais\u012bt\u0101 imunit\u0101te \u0101tri izz\u016bd.<\/strong><\/em>\u201e<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/1629334\/\" target=\"_blank\" rel=\"noreferrer noopener\">(9a)<\/a> \u201e<em><strong>Rezum\u0113jot var secin\u0101t, ka ne iepriek\u0161\u0113ja vakcin\u0101cija, ne nosak\u0101ms SIR negarant\u0113 aizsargimunit\u0101ti. Masalu v\u012bruss var izrais\u012bt asimptom\u0101tisku SIR IgG-seropozit\u012bviem indiv\u012bdiem. SVF izrais\u012bja tipiskas vai modific\u0113tas masalas, bet ne\u0161\u0137iet, ka tai b\u016btu bijusi svar\u012bga noz\u012bme \u0161\u012bs epid\u0113mijas laik\u0101.<\/strong><\/em>\u201e<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kop\u0161 2023. gada augusta, pateicoties jut\u012bg\u0101kai gad\u012bjumu defin\u012bcijai, NAVKO gad\u012bjumu skait\u0101 ir iek\u013cauti ar\u012b gad\u012bjumi ar v\u0101j\u0101kiem simptomiem un pozit\u012bvu PCR noteik\u0161anu. <a href=\"https:\/\/www.rki.de\/DE\/Themen\/Infektionskrankheiten\/Impfen\/Eliminationsprogramme\/Nationale-Verifizierungskommission-Masern-Roeteln\/Berichte\/Bericht_2021.html?templateQueryString=mit+abgeschw%C3%A4chten+Symptomen+und+positivem+PCR-Nachweis\" target=\"_blank\" rel=\"noreferrer noopener\">(10)<\/a>, ieskaitot t\u0101 saukt\u0101s \u201evakc\u012bnas masalas\u201c, t.i., masal\u0101m l\u012bdz\u012bgus \u0101das izsitumus p\u0113c vakcin\u0101cijas, v\u0113lamais m\u0113r\u0137is tagad ir piln\u012bgi nesasniedzams.<br>To, ka visa \u0161\u012b konstrukcija par it k\u0101 iesp\u0113jamu gadsimtiem senas b\u0113rnu slim\u012bbas izskau\u0161anu ar vakcin\u0101ciju var b\u016bt tikai pasaka, apstiprina jaun\u0101ka p\u0113t\u012bjuma rezult\u0101ti, kas veikts 2024. gada apr\u012bl\u012b. <a href=\"https:\/\/www.medrxiv.org\/content\/10.1101\/2024.04.18.24306028v1.full.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">(11)<\/a>:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201e<strong><em>M\u016bsu rezult\u0101ti liecina, ka vakc\u012bna pasarg\u0101 no masalu infekcijas gadu desmitiem, bet arvien liel\u0101ka iesp\u0113ja, ka infic\u0113sies cilv\u0113ki vecum\u0101 no 15 gadiem un vec\u0101ki.<\/em><\/strong>\u201e, <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">kur\u0101 izdev\u0101s pier\u0101d\u012bt, ka vakcin\u0101cijas aizsarg\u0101jo\u0161\u0101 iedarb\u012bba laika gait\u0101 samazin\u0101s, izraisot bie\u017e\u0101kus slim\u012bbas uzliesmojumus.<br>Tas skaidri par\u0101da, ka vakcin\u0101cijai pret masal\u0101m ir pret\u0113js efekts.<br>Iest\u0101des un tiesas, pamatojot masalu aizsardz\u012bbas likum\u0101 paredz\u0113tos pas\u0101kumus, vienm\u0113r atsaucas uz to.<br>Roberta Koha instit\u016btu (RKI) un t\u0101 Past\u0101v\u012bgo vakcin\u0101cijas komiteju (STIKO) k\u0101 suver\u0113nu un neatkar\u012bgu zin\u0101tnisku strukt\u016bru. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tom\u0113r \u0161\u012b klasifik\u0101cija ir nepareiza. Koronav\u012brusa pand\u0113mijas laik\u0101 2024. gad\u0101 public\u0113tie RKI \u017eurn\u0101li (\u201eRKI lietas\u201c) liecina, ka \u0161\u012bs iest\u0101des ner\u012bkoj\u0101s neatkar\u012bgi,<br>bet ir saisto\u0161i feder\u0101l\u0101 vesel\u012bbas ministra nor\u0101d\u012bjumi, un \u0161is v\u0113rt\u0113jums tika apstiprin\u0101ts 2025. gada septembr\u012b RKI prezidenta Larsa Schaade v\u0113stul\u0113 pieciem \u0137\u012bmijas profesoriem.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.berliner-zeitung.de\/politik-gesellschaft\/professoren-decken-auf-im-rki-schlaegt-die-politik-die-wissenschaft-li.2357637\" target=\"_blank\" rel=\"noreferrer noopener\">(12)<\/a> Michael Meier, Berliner Zeitung no 19\/09\/2025 - Profesori bez seguma: Politika p\u0101rsp\u0113j zin\u0101tni RKI<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">STIKO nav br\u012bvs no intere\u0161u konfliktiem. Daudzi t\u0101s locek\u013ci ir sa\u0146\u0113mu\u0161i tie\u0161u vai netie\u0161u finans\u0113jumu p\u0113tniec\u012bbai no farm\u0101cijas nozares vai atbalstu no NVO, piem\u0113ram, Bila un Melindas Geitsu fonda.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">(13) - Bahner, Beate , \u201eMeasles vaccination and measles protection law\u201c Sept. 2025, ISBN: 978-3-98992-133-7 86.-90. lpp.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Maz zin\u0101ms, bet p\u0113c b\u016bt\u012bbas skandalozs fakts ir tas, ka visi vakc\u012bnu ra\u017eot\u0101ji ir atbr\u012bvoti no jebk\u0101das atbild\u012bbas par produktiem, lai gan vakc\u012bnas, at\u0161\u0137ir\u012bb\u0101 no citu medikamentu ra\u017eot\u0101jiem, var rad\u012bt lielu kait\u0113jumu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Atbild\u012bbu par vakcin\u0101cijas rad\u012btajiem zaud\u0113jumiem uz\u0146emas valsts, kas iev\u0113rojami ierobe\u017eo kompens\u0101cijas iesp\u0113jas vakcin\u0101cijas upuriem. Oblig\u0101t\u0101 vakcin\u0101cija rada milz\u012bgus finansi\u0101lus ieguvumus lielajiem farm\u0101cijas uz\u0146\u0113mumiem - uz sabiedr\u012bbas r\u0113\u0137ina. Un tas v\u0113l nav viss: divi liel\u0101kie farm\u0101cijas uz\u0146\u0113mumi, kas ra\u017eo V\u0101cij\u0101 at\u013caut\u0101s kombin\u0113t\u0101s vakc\u012bnas pret masal\u0101m, p\u0113d\u0113jos gados un desmitgad\u0113s vair\u0101kk\u0101rt ir sod\u012bti, lai samaks\u0101tu miljardiem lielas soda naudas par da\u017e\u0101diem p\u0101rk\u0101pumiem.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.amazon.de\/Masernimpfung-Masernschutzgesetz-Zwischen-Medizin-Vernunft\/dp\/3989921339\" target=\"_blank\" rel=\"noreferrer noopener\">(14)<\/a> - Bahner, Beate - \u201eVakcin\u0101cija pret masal\u0101m un ties\u012bbu akti par aizsardz\u012bbu pret masal\u0101m\u201c - 2025. gada septembris - ISBN 978-3-98992-133-7 99.-103. lpp.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.routledge.com\/Deadly-Medicines-and-Organised-Crime-How-Big-Pharma-Has-Corrupted-Healthcare\/Gotzsche\/p\/book\/9781846198847\" target=\"_blank\" rel=\"noreferrer noopener\">(15)<\/a> - Peter Gotzsche - \u201eN\u0101v\u0113jo\u0161as z\u0101les un organiz\u0113t\u0101 noziedz\u012bbaK\u0101 liel\u0101 farm\u0101cija ir korump\u0113jusi vesel\u012bbas apr\u016bpi\u201c - 2014 - ISBN 978-1-84619-884-7<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%E2%80%A6_ist_medizinisch_sinnlos\"><\/span>... ir medic\u012bniski bezj\u0113dz\u012bga<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Liel\u0101kaj\u0101 da\u013c\u0101 gad\u012bjumu masalas ir pavisam neparasta b\u0113rnu saslim\u0161ana, nevis \u0101rk\u0101rt\u012bgi b\u012bstama slim\u012bba, par k\u0101du to bie\u017ei att\u0113lo daudzu pla\u0161sazi\u0146as l\u012bdzek\u013cu rakstos un vakcin\u0101cijas lobija propagandas film\u0101s.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Slim\u012bba parasti ir nekait\u012bga, ja izvair\u0101s no drud\u017ea samazin\u0101\u0161anas. Drudzis ir svar\u012bga dziednieciska reakcija, kuru nedr\u012bkst trauc\u0113t, ja vien iesp\u0113jams. Sare\u017e\u0123\u012btas masalu norises galvenok\u0101rt rodas, ja, piem\u0113ram, \u0101rstniecisk\u0101 reakcija tiek trauc\u0113ta, samazinot drudzi ar medikamentiem, vai ja b\u0113rniem ir D un A vitam\u012bna defic\u012bts.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Augst\u0101 dzimst\u012bbas l\u012bme\u0146a 60. gados Rietumv\u0101cij\u0101, kad joproj\u0101m bija vair\u0101k nek\u0101 1 miljons saslim\u0161anas gad\u012bjumu gad\u0101, tika re\u0123istr\u0113ti tikai aptuveni 50-150 n\u0101ves gad\u012bjumi gad\u0101, kas atbilst \u013coti zemam mirst\u012bbas r\u0101d\u012bt\u0101jam - 1 uz 10 000 iedz\u012bvot\u0101ju.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.thalia.de\/shop\/home\/artikeldetails\/A1069489158\" target=\"_blank\" rel=\"noreferrer noopener\">(16)<\/a> - Shepherd, Martin Dr , \u201eIMPFEN pro &amp;contra\u201c 2023, ISBN: 978-3-426-44872-4 270 lpp. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">RKI par to pazi\u0146oja 1999. gad\u0101.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">(17) - Hirte, Martin Dr , \u201eIMPFEN pro &amp;contra\u201c 2023, ISBN: 978-3-426-44872-4 274. lpp.<br>(18) - Bahner, Beate , \u201eMeasles Vaccination and Measles Protection Act\u201c, 2025. gada septembris, ISBN: 978-3-98992-133-7, 63. lpp.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">PVO vai citu vakcin\u0101cijas aizst\u0101vju min\u0113tais mirst\u012bbas r\u0101d\u012bt\u0101js 1:1000 \u0161aj\u0101 valst\u012b ir neprec\u012bzs un nepie\u013caujami p\u0101r\u0146emts no jaunatt\u012bst\u012bbas valst\u012bm.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kop\u0161 p\u0113d\u0113j\u0101 ap\u0161aub\u0101m\u0101 n\u0101ves gad\u012bjuma no masal\u0101m V\u0101cij\u0101 2019. gad\u0101 nav zi\u0146ots ne par vienu n\u0101ves gad\u012bjumu. V\u0101cij\u0101 n\u0101ves gad\u012bjumi no masal\u0101m ir retums, un, visticam\u0101k, tie ir saist\u012bti ar nepareizu \u0101rst\u0113\u0161anu, nevis pa\u0161u slim\u012bbu. Ilgi pirms vakcin\u0101cijas pret masal\u0101m ievie\u0161anas mirst\u012bbas r\u0101d\u012bt\u0101js no masal\u0101m V\u0101cij\u0101 jau bija samazin\u0101jies l\u012bdz \u013coti zemam l\u012bmenim, kas tuvojas nullei.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">(19) - Buchwald, Gerhard Dr., gr\u0101mata: \u201eImpfen - Das Gesch\u00e4ft mit der Angst\u201c, 133. lpp. un turpm\u0101k. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Masalu izrais\u012btas komplik\u0101cijas vairs nebija probl\u0113ma pat pirms vakc\u012bnas ievie\u0161anas. \u013boti retajos gad\u012bjumos, kad slim\u012bbas norit\u0113ja komplic\u0113ti, p\u0101rsvar\u0101 cieta b\u0113rni, kas jau bija imuniz\u0113ti vai bija \u013coti pak\u013cauti imuniz\u0101cijai.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">P\u0113c saslim\u0161anas ar masal\u0101m jums tiek nodro\u0161in\u0101ta imunit\u0101te uz visu m\u016b\u017eu, t\u0101d\u0113j\u0101di j\u016bs esat pasarg\u0101ts no atk\u0101rtotas saslim\u0161anas ar masal\u0101m l\u012bdz m\u016b\u017ea beig\u0101m. Turpret\u012b vakcin\u0101cija lab\u0101kaj\u0101 gad\u012bjum\u0101 nodro\u0161ina tikai \u012bslaic\u012bgu aizsardz\u012bbu, jo t\u0101 izraisa tikai iev\u0113rojami zem\u0101ku antivielu l\u012bmeni un maz\u0101ku \u0161\u016bnu im\u016bnstimul\u0101ciju nek\u0101 dabiska infekcija.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tas izskaidro faktu, ka pa\u0161laik 134-2,920% no masalu saslim\u0161anas gad\u012bjumiem ir saist\u012bti ar vakcin\u0113tiem cilv\u0113kiem, kas var izskaidrot ar\u012b jaunos masalu uzliesmojumus, kuri vair\u0101kk\u0101rt tiek izmantoti bai\u013cu uzkurin\u0101\u0161anai. \u0160o nep\u0101rprotami pretprodukt\u012bvo vakcin\u0101cijas pret masal\u0101m ietekmi apstiprina p\u0113t\u012bjums. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/1629334\/\" target=\"_blank\" rel=\"noreferrer noopener\">(9a)<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">kas liecina, ka laika gait\u0101 samazinoties vakcin\u0101cijas aizsardz\u012bbai, neizb\u0113gami rodas slim\u012bbu uzliesmojumi. Jo augst\u0101ks ir vakcin\u0101cijas l\u012bmenis pret masal\u0101m, jo liel\u0101ka ir viet\u0113jo epid\u0113miju iesp\u0113jam\u012bba, jo vakcin\u0101cija nerada past\u0101v\u012bgu imunit\u0101ti. T\u0101p\u0113c vakcin\u0113tai popul\u0101cijai ir daudz zem\u0101ka imunit\u0101te nek\u0101 popul\u0101cijai, kur\u0101 liel\u0101k\u0101 da\u013ca cilv\u0113ku ir saslimu\u0161i ar masal\u0101m b\u0113rn\u012bb\u0101. Tas attiecas uz<br>Pa\u0161laik gandr\u012bz puse V\u0101cijas iedz\u012bvot\u0101ju, proti, praktiski visi, kas dzimu\u0161i pirms 1970. gada, joproj\u0101m dz\u012bvo \u0161aj\u0101 valst\u012b.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Agr\u0101k z\u012bdai\u0146i tikpat k\u0101 nekad neslimoja ar masal\u0101m, jo vi\u0146us aizsarg\u0101ja antivielas, ko vi\u0146i sa\u0146\u0113ma caur placentu un m\u0101tes pienu k\u0101 t\u0101 saukto \u201eligzdveida aizsardz\u012bbu\u201c, kas vi\u0146u m\u0101t\u0113m bija pietiekam\u0101 daudzum\u0101, pateicoties pa\u0161u b\u0113rn\u012bb\u0101 ieg\u016btaj\u0101m masal\u0101m.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">T\u0101 k\u0101 vakcin\u0113t\u0101m m\u0101t\u0113m parasti ir zem\u0101ks antivielu l\u012bmenis un t\u0101p\u0113c t\u0101s var nodot maz\u0101k antivielu saviem b\u0113rniem, lai aizsarg\u0101tu to ligzdi\u0146u, kop\u0161 vakcin\u0101cijas ievie\u0161anas ar masal\u0101m ir saslimu\u0161i vair\u0101k z\u012bdai\u0146u, kas savuk\u0101rt palielina komplik\u0101ciju risku. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">T\u0101d\u0113\u013c kop\u0161 vakcin\u0101cijas pret masal\u0101m ievie\u0161anas vis\u0101 pasaul\u0113 ir palielin\u0101jies smagu saslim\u0161anas gad\u012bjumu skaits.<br>\u0160\u012b situ\u0101cija tiek nodota n\u0101kamaj\u0101m paaudz\u0113m. Citiem v\u0101rdiem sakot, tikl\u012bdz m\u0101tes ir vakcin\u0113tas pret masal\u0101m, ar\u012b b\u0113rni ir agri vakcin\u0113jami, lai izvair\u012btos no \u013coti ret\u0101m augsta riska gait\u0101m, piem\u0113ram, encefal\u012bta. Vakcin\u0113tie b\u0113rni zaud\u0113 masalu infekcijas imunomodul\u0113jo\u0161\u0101s priek\u0161roc\u012bbas. <br>Princip\u0101 \u0161\u012b probl\u0113ma attiecas ar\u012b uz vis\u0101m cit\u0101m vakcin\u0101cij\u0101m pret b\u0113rnu slim\u012bb\u0101m.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Saslim\u0161ana ar masal\u0101m sniedz daudz dabisku labumu vesel\u012bbai, jo masalas stiprina un stabiliz\u0113 \u0161\u016bnu im\u016bnsist\u0113mu, kurai ir galven\u0101 loma im\u016bnsist\u0113mas aizsardz\u012bb\u0101.<br>Ir zi\u0146as par daudz\u0101m hronisk\u0101m slim\u012bb\u0101m, kas var izzust p\u0113c masalu infekcijas. Piem\u0113ram, cilv\u0113kiem, kuri ir p\u0101rcietu\u0161i masalu infekciju, ir maz\u0101ka iesp\u0113ja saslimt ar da\u017eu veidu v\u0113zi, multiplo sklerozi un cit\u0101m autoim\u016bn\u0101m slim\u012bb\u0101m vai aler\u0123ij\u0101m.<br>21 P\u0113c saslim\u0161anas ar masal\u0101m b\u0113rni bie\u017ei vien izdara att\u012bst\u012bbas l\u0113cienu, k\u0101 rezult\u0101t\u0101, piem\u0113ram, var izzust stost\u012b\u0161an\u0101s vai slapj\u0161nas slauc\u012b\u0161ana.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pret\u0113ji visp\u0101rpie\u0146emtajam apgalvojumam, vakcin\u0101cija pret masal\u0101m ir tikai bez blakuspar\u0101d\u012bb\u0101m. Tikai no 2001. l\u012bdz 2012. gadam Paula \u0112rliha instit\u016bt\u0101, kas atbild par vakcin\u0101ciju, tika sa\u0146emti vair\u0101k nek\u0101 1300 zi\u0146ojumi par nopietn\u0101m blakuspar\u0101d\u012bb\u0101m un 15 n\u0101ves gad\u012bjumiem saist\u012bb\u0101 ar vakcin\u0101ciju.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Vair\u0101ki \u0101rsti un zin\u0101tnieki ir sal\u012bdzin\u0101ju\u0161i pa\u0161reiz\u0113jos skait\u013cus un non\u0101ku\u0161i pie skaidra secin\u0101juma, ka risks saslimt ar nopietn\u0101m vakcin\u0101cijas blakuspar\u0101d\u012bb\u0101m vai nomirt vakcin\u0101cijas rezult\u0101t\u0101 ir iev\u0113rojami liel\u0101ks nek\u0101 risks saslimt ar nopietn\u0101m masalu komplik\u0101cij\u0101m vai pat nomirt no masal\u0101m.<br>Prof. (ret.) Dr. Andreas S\u00f6nnichsen ir analiz\u0113jis pa\u0161reiz\u0113jo epidemiolo\u0123isko situ\u0101ciju.<br>apr\u0113\u0137ina \u0161\u0101di: No indiv\u012bda viedok\u013ca (skait\u013ci balst\u012bti uz 2024. gada datiem):<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Risks saslimt ar masal\u0101m V\u0101cij\u0101 pa\u0161laik ir 0,0007 % gad\u0101.<\/li>\n\n\n\n<li>Risks saslimt ar nopietn\u0101m masalu komplik\u0101cij\u0101m ir 0,0000007 % gad\u0101.<br>(pie\u0146emot, ka uz 1000 gad\u012bjumiem ir viena nopietna komplik\u0101cija).<\/li>\n\n\n\n<li>Risks nomirt no masal\u0101m ir 0,00000007 % gad\u0101, risks dz\u012bves laik\u0101 ir 0,000006 %.<br>(pie\u0146emot, ka infekcijas mirst\u012bbas l\u012bmenis ir 0,01 %).<\/li>\n\n\n\n<li>Risks, ka 1 200 000 vakcin\u0101ciju gad\u0101 izrais\u012bs nopietnas blakuspar\u0101d\u012bbas, ir \u0161\u0101ds.<br>un aptuveni 50 smagas blakuspar\u0101d\u012bbas gad\u0101 0,004 %.<br>Tas ir 6 reizes liel\u0101ks nek\u0101 risks saslimt ar masal\u0101m un 5700 rei\u017eu liel\u0101ks nek\u0101 risks saslimt ar masal\u0101m,<br>nopietnas masalu komplik\u0101cijas.<\/li>\n\n\n\n<li>Mirst\u012bbas risks saist\u012bb\u0101 ar vakcin\u0101ciju ir 0,0013 %.<br>(pie\u0146emot 1-2 n\u0101ves gad\u012bjumus gad\u0101, kas nav oblig\u0101ti saist\u012bti ar c\u0113lo\u0146sakar\u012bbu).<br>Tas ir vair\u0101k nek\u0101 200 rei\u017eu liel\u0101ks nek\u0101 risks visa m\u016b\u017ea laik\u0101 nomirt no masal\u0101m.<br>\u0160\u012b \u0101rk\u0101rt\u012bgi negat\u012bv\u0101 riska un ieguvuma attiec\u012bba pati par sevi ir medic\u012bniska kontrindik\u0101cija vakcin\u0101cijai pret masal\u0101m, kas ir j\u0101apliecina katram atsevi\u0161\u0137am b\u0113rnam, pat ja vi\u0146\u0161 iepriek\u0161 nav slimojis, k\u0101 da\u013ca no imuniz\u0101cijas apliec\u012bbas.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">L\u012bdz \u0161im nav veikts neviens p\u0113t\u012bjums, kur\u0101 vakc\u012bna b\u016btu p\u0101rbaud\u012bta sal\u012bdzin\u0101jum\u0101 ar nevakcin\u0113tu kontroles grupu ilg\u0101k\u0101 laika posm\u0101. Nav ar\u012b atbilsto\u0161u dro\u0161\u012bbas p\u0113t\u012bjumu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Augsta ranga vakcin\u0101cijas aizst\u0101vju 2024. gada p\u0113t\u012bjum\u0101 autori atzina, ka nav iesp\u0113jams nov\u0113rt\u0113t ieguvumu\/riska attiec\u012bbu starp vienu vakcin\u0101ciju, jo tr\u016bkst p\u0113t\u012bjumu ar pietiekami liel\u0101m sal\u012bdzino\u0161aj\u0101m grup\u0101m pietiekami ilg\u0101 laika posm\u0101.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.nejm.org\/doi\/10.1056\/NEJMp2402379?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed\" target=\"_blank\" rel=\"noreferrer noopener\">(22)<\/a> Salmon DA et al: Postautoriz\u0101cijas zin\u0101tnisko p\u0113t\u012bjumu par vakc\u012bnu dro\u0161\u012bbu finans\u0113\u0161ana. N Engl J Med 2024; 391.2:102-5<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Vakc\u012bnu ra\u017eot\u0101ji apzin\u0101ti sl\u0113pj datus par vakc\u012bnu dro\u0161\u012bbu, jo lielu da\u013cu pas\u016bt\u012bto vakc\u012bnu dro\u0161\u012bbas p\u0113t\u012bjumu nekad nepublic\u0113, jo rezult\u0101ti ir \u013coti negat\u012bvi un ar universit\u0101t\u0113m vai speci\u0101listu grup\u0101m, kas veic p\u0113t\u012bjumus, jau iepriek\u0161 ir nosl\u0113gti nepublic\u0113\u0161anas un inform\u0101cijas neizpau\u0161anas l\u012bgumi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMsa044115\" target=\"_blank\" rel=\"noreferrer noopener\">(23)<\/a> \u201eNo 122 uzrun\u0101taj\u0101m iest\u0101d\u0113m piedal\u012bj\u0101s 107. Administratoru vid\u016b vald\u012bja liela vienpr\u0101t\u012bba par vair\u0101ku ar publik\u0101cij\u0101m saist\u012btu l\u012bguma noteikumu pie\u0146emam\u012bbu. Piem\u0113ram, vair\u0101k nek\u0101 85 % nor\u0101d\u012bja, ka vi\u0146u birojs neapstiprin\u0101tu noteikumus, kas nozares sponsoriem pie\u0161\u0137ir ties\u012bbas p\u0101rskat\u012bt manuskriptus vai lemt par rezult\u0101tu public\u0113\u0161anu. Past\u0101v iev\u0113rojamas domstarp\u012bbas par to, vai ir pie\u0146emami noteikumi, kas sponsoram \u013cauj iek\u013caut manuskriptos savu statistisko anal\u012bzi (24 % to at\u013cauj, 47 % neat\u013cauj un 29 % nav p\u0101rliecin\u0101ti, vai to at\u013caut), izstr\u0101d\u0101t manuskriptu (50 % to at\u013cauj, (50 procenti to at\u013c\u0101va, 40 procenti atteica un 11 procenti nebija p\u0101rliecin\u0101ti, vai to at\u013caut) un aizliegt p\u0113tniekiem izpaust datus tre\u0161\u0101m person\u0101m p\u0113c p\u0113t\u012bjuma pabeig\u0161anas (41 procents to at\u013c\u0101va, 34 procenti atteica un 24 procenti nebija p\u0101rliecin\u0101ti, vai to at\u013caut). Str\u012bdi bie\u017ei rad\u0101s p\u0113c l\u012bgumu parakst\u012b\u0161anas, un visbie\u017e\u0101k tie bija saist\u012bti ar maks\u0101jumiem (75 procenti administratoru zi\u0146oja par vismaz vienu \u0161\u0101du str\u012bdu iepriek\u0161\u0113j\u0101 gad\u0101), intelektu\u0101lo \u012bpa\u0161umu (30 procenti) un datu kontroli vai piek\u013cuvi datiem (17 procenti)\u201c.\u201c<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/api.aerzteblatt.de\/pdf\/104\/28\/a2030.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">(24)<\/a> \u201eTas, kas aizskar visp\u0101r\u0113ju piekl\u0101j\u012bbu, ir sp\u0113k\u0101 neeso\u0161s\u201c<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ikvienam vajadz\u0113tu b\u016bt ac\u012bmredzamam, ka tas ir nepie\u0146emami maldino\u0161s zin\u0101tnisks izkrop\u013cojums.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">St\u0101stam par nevakcin\u0113tu b\u0113rnu kategoriz\u0113\u0161anu k\u0101 b\u012bstamu sabiedr\u012bbai, k\u0101 m\u0113s to piedz\u012bvoj\u0101m krona pand\u0113mijas laik\u0101, nav ne medic\u012bniska, ne zin\u0101tniska pamatojuma. V\u0101cij\u0101 katru gadu no da\u017e\u0101d\u0101m infekcijas slim\u012bb\u0101m mirst vair\u0101k nek\u0101 100 b\u0113rnu, bet no masal\u0101m - ne viens. T\u0101p\u0113c maz\u0101k aizsarg\u0101tie b\u0113rni, piem\u0113ram, b\u0113rni ar nov\u0101jin\u0101tu imunit\u0101ti, mirst no cit\u0101m infekcij\u0101m, un to nevar nov\u0113rst ar oblig\u0101tu vakcin\u0101ciju pret masal\u0101m.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Vakcin\u0101cijas aizst\u0101vjiem pat\u012bk argument\u0113t par labu \u201egan\u0101mpulka imunit\u0101tei\u201c. Tad neimunus cilv\u0113kus no infekcijas pasarg\u0101tu liela da\u013ca im\u016bno (vakcin\u0113to) l\u012bdzcilv\u0113ku. Tom\u0113r \u201egan\u0101mpulka imunit\u0101tes\u201c arguments nav pie\u013caujams, jo \u0161is termins, kas c\u0113lies no veterin\u0101rmedic\u012bnas, attiecas tikai uz dabisk\u0101 ce\u013c\u0101 ieg\u016bt\u0101m slim\u012bb\u0101m, kas v\u0113l\u0101k rada past\u0101v\u012bgu imunit\u0101ti.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7123916\/\" target=\"_blank\" rel=\"noreferrer noopener\">(25)<\/a> Hedrich A: Epid\u0113miskie p\u0113t\u012bjumi: John Hopkins University, Baltimore; Maryland (ASV) 1933: The Monthly Variation of Measles Susceptibles in Baltimore, Maryland from 1901 to 1928 - John Hopkins University, Baltimore; Maryland (USA) 1933<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Neviena vakcin\u0101cija nerada ilgsto\u0161u imunit\u0101ti, t\u0101p\u0113c nevienu slim\u012bbu nevar izskaust. Vakcin\u0113tie cilv\u0113ki var ne tikai saslimt pa\u0161i, bet ar\u012b nodot patog\u0113nus citiem.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/8053748\/\" target=\"_blank\" rel=\"noreferrer noopener\">(26)<\/a> \u201eAc\u012bmredzams paradokss ir tas, ka, palielinoties masalu vakcin\u0101cijas p\u0101rkl\u0101jumam popul\u0101cij\u0101, masalas k\u013c\u016bst par imuniz\u0113to indiv\u012bdu slim\u012bbu. Sakar\u0101 ar vakc\u012bnas neveiksmju bie\u017eumu un masalu v\u012brusa unik\u0101lo p\u0101rn\u0113s\u0101jam\u012bbu ir maz ticams, ka pa\u0161laik pieejam\u0101 masalu vakc\u012bna, ko izmanto vienas devas strat\u0113\u0123ij\u0101, var\u0113tu piln\u012bb\u0101 izskaust masalas. Divu vakcin\u0101cijas devu vakcin\u0101cijas strat\u0113\u0123ijas ilgtermi\u0146a pan\u0101kumi masalu izskau\u0161an\u0101 v\u0113l ir j\u0101nosaka.\u201c<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">To apstiprina ar\u012b RKI dati.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.rki.de\/DE\/Aktuelles\/Publikationen\/Epidemiologisches-Bulletin\/2024\/04_24.pdf?__blob=publicationFile&amp;v=4\" target=\"_blank\" rel=\"noreferrer noopener\">(27)<\/a> Epid\u0113mijas bi\u013cetens no 2024. gada apr\u012b\u013ca<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">saska\u0146\u0101 ar kuru aptuveni 15 l\u012bdz 22 % infic\u0113\u0161an\u0101s gad\u012bjumu sk\u0101ra vakcin\u0113tus cilv\u0113kus. Vis\u0101 Eirop\u0101 14 % no 2023. gad\u0101 re\u0123istr\u0113tajiem masalu gad\u012bjumiem bija vakcin\u0113ti vienu vai divas reizes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/MEAS_AER_2023_Report.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">(28)<\/a> \u201e<strong><em>2023. gad\u0101 masalu saslim\u0161anas gad\u012bjumi tika re\u0123istr\u0113ti vis\u0101s vecuma grup\u0101s, un visliel\u0101kais kop\u0113jais saslim\u0161anas gad\u012bjumu \u012bpatsvars bija vis\u0101s vecuma grup\u0101s.<br>nevakcin\u0113t\u0101m person\u0101m (86 %) ir nov\u0113rota p\u0113d\u0113jo piecu gadu laik\u0101.<\/em><\/strong>\u201e<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Masalu uzliesmojuma laik\u0101 ASV 18,4 % no infic\u0113tajiem bija vakcin\u0113ti vismaz vienu reizi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">(29) Slim\u012bbu kontroles un profilakses centrs: \u00bbMasalas. Amerikas Savienot\u0101s Valstis, 1990. gads\u00ab, ikned\u0113\u013cas zi\u0146ojums par saslimst\u012bbu un mirst\u012bbu, 1991, 40:369-372.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L\u012bdz\u012bg\u0101 gad\u012bjum\u0101 Braz\u012blij\u0101 vakcin\u0113j\u0101s 32,7 % no infic\u0113tajiem.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/14715557\/\" target=\"_blank\" rel=\"noreferrer noopener\">(30)<\/a> \u201e<strong><em>No 159 pacientiem 107 (67,3 %) nebija vakcin\u0113ti un 52 (32,7 %) bija sa\u0146\u0113mu\u0161i vienu vai vair\u0101kas masalu vakc\u012bnas devas.<\/em><\/strong>\u201e<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tas vien, ka noteikta procentu\u0101l\u0101 da\u013ca (aptuveni 16%)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/link.springer.com\/article\/10.1007\/BF03404484\" target=\"_blank\" rel=\"noreferrer noopener\">(31)<\/a> \u201e... <strong><em>16,4 % un 22,4 % vakcin\u0113to personu nebija nosak\u0101mas antivielas pret masal\u0101m un epid\u0113misko parot\u012btu, attiec\u012bgi<\/em><\/strong> ...\u201c<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">notiek \u201evakcin\u0101cijas neveiksme\u201c, t. i., antivielu veido\u0161an\u0101s nenotiek, neraugoties uz vakcin\u0101ciju, turkl\u0101t \u201eveiksm\u012bgi vakcin\u0113to\u201c antivielu l\u012bmenis \u0101tri samazin\u0101s un l\u012bdz ar to ar\u012b imunit\u0101te, nevar b\u016bt v\u0113lamais 95 % imunit\u0101tes l\u012bmenis. Pat dabisk\u0101s imunit\u0101tes gad\u012bjum\u0101, ko izraisa masalu infekcija, epid\u0113mijas p\u0101rtrauk\u0161anai pietiek ar ne vair\u0101k k\u0101 60 %.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7239079\/\" target=\"_blank\" rel=\"noreferrer noopener\">(33)<\/a> \u201e<strong><em>Jo \u012bpa\u0161i m\u016bsu veikt\u0101s anal\u012bzes liecina, ka variantam specifiskai, dabiski ieg\u016btajai imunit\u0101tei bija daudz liel\u0101ka noz\u012bme, nek\u0101 var\u0113ja sagaid\u012bt, pamatojoties uz mode\u013ciem, kuros maz\u0101k \u0146emtas v\u0113r\u0101 individu\u0101l\u0101s at\u0161\u0137ir\u012bbas uz\u0146\u0113m\u012bbas un pak\u013caut\u012bbas infekcijai zi\u0146\u0101 (atcerieties, ka mode\u013cos, kuros pie\u0146emts, ka imunit\u0101te ir homog\u0113na, gan\u0101mpulka imunit\u0101tes slieksnis paaugstin\u0101ts l\u012bdz 60 % un vair\u0101k).<\/em><\/strong>\u201e<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.medrxiv.org\/content\/10.1101\/2020.07.15.20154294v1\" target=\"_blank\" rel=\"noreferrer noopener\">(34)<\/a> \u201e<strong><em>Parasti tiek pie\u0146emts, ka gan\u0101mpulka imunit\u0101tes slieksnis (HIT), kas nepiecie\u0161ams, lai nov\u0113rstu SARS-CoV-2 atjauno\u0161anos, ir virs 50% jebkur\u0101 epidemiolo\u0123isk\u0101 vid\u0113.<\/em><\/strong>\u201e<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Subak\u016bts skleroz\u0113jo\u0161s panencefal\u012bts jeb sa\u012bsin\u0101jum\u0101 SSPE, ko Feder\u0101l\u0101 vesel\u012bbas ministrija min k\u0101 iesp\u0113jam\u0101s v\u0113l\u012bn\u0101s masalu sekas k\u0101 argumentu oblig\u0101t\u0101s vakcin\u0101cijas pret masal\u0101m nepiecie\u0161am\u012bbai un Feder\u0101l\u0101s konstitucion\u0101l\u0101s tiesas l\u0113muma par dienas apr\u016bpes centru pamatojum\u0101, ir \u0101rk\u0101rt\u012bgi reta slim\u012bba. No 2013. l\u012bdz 2022. gadam V\u0101cij\u0101 bija tikai 29 saslim\u0161anas gad\u012bjumi, t. i., vid\u0113ji maz\u0101k nek\u0101 3 gad\u012bjumi gad\u0101.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">(35) Bahner, Beate, \u201eMeasles Vaccination and Measles Protection Act\u201c, 2025. gada septembris, ISBN: 978-3-98992-133-7 240.-258. lpp.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u0160is pak\u0101peniski progres\u0113jo\u0161ais smadze\u0146u iekaisums, kas vairum\u0101 gad\u012bjumu beidzas ar n\u0101vi, vid\u0113ji rodas aptuveni 7 l\u012bdz 10 gadus p\u0113c infic\u0113\u0161an\u0101s ar masal\u0101m, \u012bpa\u0161i z\u012bdai\u0146a vai agr\u012bn\u0101 b\u0113rn\u012bb\u0101.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tom\u0113r joproj\u0101m nav skaidrs, vai iepriek\u0161\u0113ja saslim\u0161ana ar masal\u0101m visp\u0101r var izrais\u012bt SSPE. Vien\u012bgais nopietnais p\u0113t\u012bjums analiz\u0113to gad\u012bjumu skaita zi\u0146\u0101 ir no ASV.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/jamanetwork.com\/journals\/jama\/article-abstract\/342424\" target=\"_blank\" rel=\"noreferrer noopener\">(36)<\/a> \u201e<strong><em>\u0160aj\u0101 zi\u0146ojum\u0101 par subak\u016bt\u0101 skleroz\u0113jo\u0161\u0101 panencefal\u012bta (SSPE) re\u0123istru no 1960. l\u012bdz 1970. gadam rezult\u0101ti liecina par 50 % saist\u012bbu starp SSPE un agr\u012bnu saslim\u0161anu ar masal\u0101m (maz\u0101k nek\u0101 2 gadu vecum\u0101). Saslimst\u012bba ar SSPE ir viens uz miljonu, un liel\u0101k\u0101 da\u013ca pacientu dz\u012bvo ASV dienvidaustrumu da\u013c\u0101.<\/em><\/strong>\u201e<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">P\u0113t\u012bjuma rezult\u0101ti liecina, ka risks saslimt ar SSPE ir gandr\u012bz neeso\u0161s - 1:1 miljonam.<br>Nav skaidrs, k\u0101 RKI non\u0101k pie SSPE riska 4-11 uz 100 000 masalu gad\u012bjumu. RKI sav\u0101 neatbilsto\u0161aj\u0101 riska nov\u0113rt\u0113jum\u0101 ac\u012bmredzami atsaucas uz metodolo\u0123iski k\u013c\u016bdainu 2013. gada publik\u0101ciju.<br>(Mana piez\u012bme: saska\u0146\u0101 ar atrunu p\u0113t\u012bjumu \u201efinans\u0113ja Bav\u0101rijas Vides un vesel\u012bbas ministrija ESPED datu v\u0101k\u0161anai un Roberta Koha instit\u016bts ar Feder\u0101l\u0101s vesel\u012bbas ministrijas l\u012bdzek\u013ciem (FKZ 1369-400). Roberta Koha instit\u016bta darbinieki sniedza datus par saslim\u0161an\u0101m ar masal\u0101m V\u0101cij\u0101, kas tika pazi\u0146otas Roberta Koha instit\u016btam, pamatojoties uz V\u0101cijas Infekciju aizsardz\u012bbas likumu. \u0160os datus autori izmantoja turpm\u0101kai anal\u012bzei...\u201c).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3706451\/\" target=\"_blank\" rel=\"noreferrer noopener\">(37)<\/a> Subak\u016bta skleroz\u0113jo\u0161a panencefal\u012bta (SSPE) epidemiolo\u0123ija V\u0101cij\u0101 no 2003. l\u012bdz 2009. gadam: riska nov\u0113rt\u0113jums<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">P\u0113t\u012bjuma autori var\u0113ja analiz\u0113t \u013coti nelielu skaitu - tikai 31 gad\u012bjumu, no kuriem 17 bija pret.<br>vakcin\u0113ti pret masal\u0101m. Tom\u0113r RKI ac\u012bmredzami k\u013c\u016bdaini apgalvo: \u201eVakc\u012bnas v\u012bruss nekad nav konstat\u0113ts slimiem cilv\u0113kiem, t\u0101p\u0113c var pie\u0146emt, ka vakcin\u0101cija pret masal\u0101m nevar izrais\u012bt SSPE.\u201c<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.rki.de\/SharedDocs\/FAQs\/DE\/Impfen\/MMR\/Masernimpfung\/FAQ-Liste_Masernimpfung.html#entry_16870994\" target=\"_blank\" rel=\"noreferrer noopener\">(38)<\/a> \u201eSubak\u016bts skleroz\u0113jo\u0161s panencefal\u012bts (SSPE) ir slim\u012bba, ko izraisa savva\u013cas masalu v\u012brusi, kas saglab\u0101jas centr\u0101laj\u0101 nervu sist\u0113m\u0101 (CNS). Vakc\u012bnas v\u012bruss pacientiem nekad nav konstat\u0113ts, t\u0101p\u0113c var pie\u0146emt, ka vakcin\u0101cija pret masal\u0101m nevar izrais\u012bt SSPE.\u201c<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">T\u0101 ir ne tikai apzin\u0101ta iedz\u012bvot\u0101ju maldin\u0101\u0161ana saist\u012bb\u0101 ar min\u0113to V\u0101cijas publik\u0101ciju, jo \u0161is RKI apgalvojums, kam, iesp\u0113jams, bija iz\u0161\u0137iro\u0161a noz\u012bme l\u0113mum\u0101 par oblig\u0101to vakcin\u0101ciju, ir pat pretrun\u0101 ar farm\u0101cijas uz\u0146\u0113muma Merck Sharp &amp; Dohme tehnisko inform\u0101ciju par tr\u012bsk\u0101r\u0161o masalu vakc\u012bnu M-M-RvaxPro, kur\u0101 nor\u0101d\u012bts: <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.fachinfo.de\/fi\/pdf\/010432\/m-m-rvaxpro-r\" target=\"_blank\" rel=\"noreferrer noopener\">(39)<\/a> \u201eIr biju\u0161i zi\u0146ojumi par SSPE b\u0113rniem, kuri nav infic\u0113ju\u0161ies ar savva\u013cas masalu v\u012brusu, bet ir sa\u0146\u0113mu\u0161i vakc\u012bnu pret masal\u0101m. Da\u017ei no \u0161iem gad\u012bjumiem var\u0113tu b\u016bt saist\u012bti ar neatz\u012btu masalu infekciju pirmaj\u0101 dz\u012bves gad\u0101 vai ar vakcin\u0101ciju pret masal\u0101m.\u201c<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Advok\u0101te Beate Bahnere raksta:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">(40) \u201eBahner, Beate , \u201eMeasles vaccination and measles protection law\u201c Sept. 2025, ISBN: 978-3-98992-133-7 lpp. 255\u201c.\u201c<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"> \u201eK\u0101 m\u0113s varam uztic\u0113ties t\u0101dai valsts instit\u016bcijai k\u0101 Roberta Koha instit\u016bts, ja t\u0101 izsaka apgalvojumus, kas jau gadiem ilgi ir zin\u0101tniski atsp\u0113koti un pat ir pretrun\u0101 ar pa\u0161a ra\u017eot\u0101ja sniegto inform\u0101ciju?\u201c<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Psihoneiroimunolo\u0123ij\u0101 ir ar\u012b publik\u0101cijas, kas nep\u0101rprotami v\u0113r\u0161as pret oblig\u0101to vakcin\u0101ciju. \u0160o p\u0113t\u012bjumu rezult\u0101ti liecina, ka stress var izrais\u012bt antivielu titra samazin\u0101\u0161anos un paaugstin\u0101tu vakcin\u0101cijas blakuspar\u0101d\u012bbu risku, samazinot im\u016bnsist\u0113mas aktivit\u0101ti.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15039506\/\" target=\"_blank\" rel=\"noreferrer noopener\">(41)<\/a> \u201eTikt\u0101l, cikt\u0101l nov\u0113ro\u0161anas period\u0101 vi\u0146i zi\u0146oja par augst\u0101ku stresa l\u012bmeni, p\u0113t\u0101maj\u0101m person\u0101m bija v\u0101j\u0101ka antivielu reakcija uz Jaunkaledonijas vakc\u012bnas celmu. Stresa nov\u0113rt\u0113jums divas dienas pirms vakcin\u0101cijas un vakcin\u0101cijas dien\u0101 nebija saist\u012bts ar antivielu reakciju. Tom\u0113r desmit dienas p\u0113c vakcin\u0101cijas, \u0161\u0137iet, bija laika posms, kur\u0101 stress da\u017e\u0101d\u0101 m\u0113r\u0101 var\u0113ja ietekm\u0113t ilgtermi\u0146a antivielu reakciju. Run\u0101jot par iesp\u0113jamajiem medi\u0101cijas ce\u013ciem, bija maz pier\u0101d\u012bjumu par kortizola izdal\u012b\u0161an\u0101s, alkohola pat\u0113ri\u0146a, fizisk\u0101s aktivit\u0101tes vai cigare\u0161u sm\u0113\u0137\u0113\u0161anas noz\u012bmi. Tom\u0113r anal\u012bze atbilda modelim, kur\u0101 stresa saj\u016bta un miega tr\u016bkums veido pa\u0161pastiprino\u0161u ciklu, kas galu gal\u0101 v\u0101jina humor\u0101lo im\u016bnsist\u0113mu. \u0160ie rezult\u0101ti var\u0113tu atkl\u0101t meh\u0101nismus, k\u0101 stress palielina uz\u0146\u0113m\u012bbu pret infekcijas slim\u012bb\u0101m.\u201e<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7841255\/\" target=\"_blank\" rel=\"noreferrer noopener\">(42)<\/a> \u201eM\u016bsu laboratorijas un daudzu citu laboratoriju p\u0113t\u012bjumos ir konstat\u0113ts, ka psiholo\u0123iskie un uzved\u012bbas faktori ir galvenie faktori, kas nosaka im\u016bnsist\u0113mas reakciju uz daudziem da\u017e\u0101diem vakc\u012bnu veidiem, pal\u012bdzot noteikt blakuspar\u0101d\u012bbu profilu un efektivit\u0101ti.\u201c<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u012apa\u0161i vec\u0101ki, kuriem pret savu gribu ir j\u0101imuniz\u0113 savi b\u0113rni, ir pak\u013cauti iev\u0113rojamam psihosoci\u0101lam spiedienam, un vi\u0146i to nodod saviem b\u0113rniem. T\u0101p\u0113c oblig\u0101t\u0101 vakcin\u0101cija izraisa ar\u012b emocion\u0101lu un fizisku vardarb\u012bbu pret b\u0113rniem.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">No imunolo\u0123isk\u0101 viedok\u013ca j\u0101pau\u017e \u0161\u0101das ba\u017eas, kas kopum\u0101 attiecas uz vis\u0101m vakcin\u0101cij\u0101m pret b\u0113rnu slim\u012bb\u0101m: ilgsto\u0161a dabisko infekciju pieredzes samazin\u0101\u0161ana, \u012bstenojot visaptvero\u0161as vakcin\u0101cijas programmas, var\u0113tu mazin\u0101t epigen\u0113tisko imprintingu un l\u012bdz ar to popul\u0101cijas imunolo\u0123isko notur\u012bbu, kas var\u0113tu palielin\u0101t uz\u0146\u0113m\u012bbu pret jauniem patog\u0113niem vai im\u016bnsist\u0113mas disregul\u0101ciju paaud\u017eu gait\u0101.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Neraugoties uz \u0161iem skaidrajiem medic\u012bniski zin\u0101tniskajiem faktiem un daudzajiem argumentiem pret vakcin\u0101ciju pret masal\u0101m, tiesu iest\u0101des v\u0113r\u0161as pret \u0101rstiem, kuri kritiski izsak\u0101s par vakcin\u0101ciju, un vi\u0146iem draud krimin\u0101lvaj\u0101\u0161ana pat tad, ja vi\u0146i izsniedz kontrindik\u0101cijas apliec\u012bbu! M\u0113s to uzskat\u0101m par nepie\u0146emamu.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Rechtsgutachten_%E2%80%93_Ist_die_Impfpflicht_nach_dem_geplanten_Masernschutzgesetz_verfassungswidrig\"><\/span>Juridiskais atzinums - Vai vakcin\u0101cijas pien\u0101kums saska\u0146\u0101 ar (pl\u0101noto) likumu par aizsardz\u012bbu pret masal\u0101m?<br>neatbilst konstit\u016bcijai?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Baireitas Universit\u0101tes Publisko ties\u012bbu, soci\u0101l\u0101s ekonomikas un vesel\u012bbas ties\u012bbu katedras Prof. Dr. Stephan Rixen 2019. gada 11. oktobra juridiskais atzinums, kas public\u0113ts 2019. gada 11. oktobra izdevum\u0101 <a href=\"https:\/\/individuelle-impfentscheidung.de\/fileadmin\/Downloads\/Rechtsgutachten_Rixen_Langfassung.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Gar\u0101 versija<\/a>. \u0160eit ir \u013coti sa\u012bsin\u0101ts kopsavilkums.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Zi\u0146ojum\u0101 analiz\u0113ta pl\u0101not\u0101s vakcin\u0101cijas pret masal\u0101m pras\u012bbas saska\u0146\u0101 ar Likumu par masalu aizsardz\u012bbu (IfSchG-E) konstitucionalit\u0101te. Galvenais secin\u0101jums ir t\u0101ds, ka pl\u0101not\u0101 oblig\u0101t\u0101 vakcin\u0101cija t\u0101s konkr\u0113taj\u0101 form\u0101 ir pretrun\u0101 konstit\u016bcijai. T\u0101 p\u0101rk\u0101pj b\u0113rnu, vec\u0101ku un \u0101rstu pamatties\u012bbas.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Betroffene_Grundrechte\"><\/span>Skart\u0101s pamatties\u012bbas<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Zi\u0146ojum\u0101 konstat\u0113ti \u0161\u0101di pamatties\u012bbu p\u0101rk\u0101pumi:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Pamatties\u012bbas uz fizisko neaizskaram\u012bbu (GG 2 II 1. pants): Vakcin\u0101cijas pien\u0101kums tie\u0161i skar \u0161\u012bs ties\u012bbas.<\/li>\n\n\n\n<li>Vec\u0101ku ties\u012bbas (GG 6 II 1. pants): Vec\u0101ki zaud\u0113 ties\u012bbas br\u012bvi lemt par medic\u012bniskiem pas\u0101kumiem attiec\u012bb\u0101 uz saviem b\u0113rniem.<\/li>\n\n\n\n<li>Vienl\u012bdz\u012bbas ties\u012bbas (GG 3. I pants): At\u0161\u0137ir\u012bga attieksme pret sal\u012bdzin\u0101m\u0101m situ\u0101cij\u0101m b\u0113rnu dienas apr\u016bpes centros, b\u0113rnu dienas apr\u016bpes iest\u0101d\u0113s un skol\u0101s nav pamatota.<\/li>\n\n\n\n<li>\u0100rstu profesion\u0101l\u0101 br\u012bv\u012bba (GG 12. I pants): \u0100rstu pien\u0101kums ir r\u012bkoties saska\u0146\u0101 ar STIKO ieteikumiem, pat ja tas ir pretrun\u0101 ar vi\u0146u medic\u012bnisko p\u0101rliec\u012bbu.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Regelungsmechanismus_und_Zwangsstruktur\"><\/span>Regulat\u012bvais meh\u0101nisms un piespiedu strukt\u016bra<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Pl\u0101notais likums darbojas, izmantojot septi\u0146as savstarp\u0113ji saist\u012btas regulas, kas rada pieaugo\u0161a spiediena meh\u0101nismu:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Pamatpien\u0101kums: \u201apar\u0101d\u012bt\u2018 vakcin\u0101cijas aizsardz\u012bbu (vakcin\u0113ties).<\/li>\n\n\n\n<li>Pien\u0101kums iesniegt pier\u0101d\u012bjumus dienas apr\u016bpes centram<\/li>\n\n\n\n<li>Aizliegums uz\u0146emt b\u0113rnus b\u0113rnud\u0101rzos, ja nav vakcin\u0101cijas<\/li>\n\n\n\n<li>Pien\u0101kums iesniegt pier\u0101d\u012bjumus vesel\u012bbas apr\u016bpes iest\u0101dei, par ko uzliek naudas sodu.<\/li>\n\n\n\n<li>Uzaicin\u0101jums uz konsult\u0101ciju un piepras\u012bjums par aizpild\u012b\u0161anu<\/li>\n\n\n\n<li>Uztur\u0113\u0161an\u0101s aizliegumi (ar t\u016bl\u012bt\u0113ju izpildi)<\/li>\n\n\n\n<li>Datu nos\u016bt\u012b\u0161ana sabiedr\u012bbas vesel\u012bbas departamentam<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Zi\u0146ojum\u0101 kritiz\u0113ts fakts, ka ar \u0161o pas\u0101kumu uzkr\u0101\u0161anu faktiski tiek anul\u0113ts vakcin\u0101cijas l\u0113muma \u201abr\u012bvpr\u0101t\u012bgais\u2018 raksturs.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Kritik_an_der_Verhaltnismasigkeit\"><\/span>Proporcionalit\u0101tes kritika<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Eksperts uzskata, ka likums ir nesam\u0113r\u012bgs:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nepiecie\u0161am\u012bba<\/strong><br>\u0145emot v\u0113r\u0101, ka vakcin\u0101cijas l\u012bmenis pirmaj\u0101 vakcin\u0101cij\u0101 bija 97,1%, bet otraj\u0101 vakcin\u0101cij\u0101 - 92,8%, rodas jaut\u0101jums, vai ir nepiecie\u0161ama piespie\u0161ana. Optimiz\u0113jot ieteikumus par vakcin\u0101ciju, m\u0113r\u0137i var\u0113tu sasniegt bez tik krasas ietekmes. Otr\u0101 vakcin\u0101cija ir \u012bpa\u0161i problem\u0101tiska b\u0113rniem, kuriem jau p\u0113c pirm\u0101s vakcin\u0101cijas ir izveidojusies imunit\u0101te, - t\u0101 kalpo tikai citu aizsardz\u012bbai.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Pamatot\u012bba<\/strong><br>Noteikumi ir nepamatoti, jo: (a) aizsardz\u012bbas koncepcija netiek \u012bstenota konsekventi (at\u0161\u0137ir\u012bga attieksme pret dienas apr\u016bpes centriem un b\u0113rnu dienas apr\u016bpes iest\u0101d\u0113m, lai gan situ\u0101cija ir sal\u012bdzin\u0101ma); b) tiek izmantotas kombin\u0113t\u0101s vakc\u012bnas pret cit\u0101m slim\u012bb\u0101m (MMR\/MMRV, nevis tikai masalu vakc\u012bnas), kas rada klusu papla\u0161in\u0101jumu.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Rechtsstaatliche_und_demokratische_Mangel\"><\/span>Tiesiskums un demokr\u0101tijas tr\u016bkumi<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u012apa\u0161\u0101 funkcija<\/strong><br>Likum\u0101 ir centr\u0101l\u0101 atsauce uz Past\u0101v\u012bg\u0101s vakcin\u0101cijas komitejas (STIKO) ieteikumiem, nepaskaidrojot, kuras to da\u013cas ir piem\u0113rojamas un k\u0101 tas ir saist\u012bts ar Saksijas Vakcin\u0101cijas komisijas (SIKO) ieteikumiem. Tas rada nepie\u0146emamu nenoteikt\u012bbu attiec\u012bb\u0101 uz tiesiskumu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Dele\u0123\u0113\u0161ana<\/strong><br>STIKO k\u013c\u016bst par faktisko likumdev\u0113ju, kas, izmantojot ieteikumus, nosaka oblig\u0101t\u0101s vakcin\u0101cijas apjomu un saturu bez efekt\u012bvas parlamenta kontroles. Tas ir pretrun\u0101 ar Pamatlikuma demokr\u0101tisko principu.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Das_Kombinationsimpfstoff-Problem\"><\/span>Kombin\u0113to vakc\u012bnu probl\u0113ma<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Galven\u0101 probl\u0113ma: likums at\u013cauj kombin\u0113t\u0101s vakc\u012bnas vis\u0101s jom\u0101s. T\u0101 k\u0101 \u0161\u012bs vakc\u012bnas ac\u012bmredzot ir pieejamas tikai V\u0101cij\u0101 (pa\u0161laik MMR vai MMRV), likums klus\u0113jot at\u013cauj to neierobe\u017eotu papla\u0161in\u0101\u0161anu. Farmaceitisk\u0101 r\u016bpniec\u012bba n\u0101kotn\u0113 var\u0113tu pievienot v\u0113l citas slim\u012bbas, un tas neb\u016btu reglament\u0113ts ar likumu. T\u0101d\u0113j\u0101di oblig\u0101t\u0101 vakcin\u0101cija pret masal\u0101m k\u013c\u016bst par de facto oblig\u0101tu vakcin\u0101ciju pret vair\u0101k\u0101m slim\u012bb\u0101m, un tas nav p\u0101rredzami reglament\u0113ts.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Fazit\"><\/span>Secin\u0101jums<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Zi\u0146ojum\u0101 secin\u0101ts, ka pl\u0101not\u0101 oblig\u0101t\u0101s vakcin\u0101cijas pret masal\u0101m programma t\u0101s pa\u0161reiz\u0113j\u0101 form\u0101 ir balst\u012bta uz. <strong>neatbilst konstit\u016bcijai vair\u0101kos aspektos.<\/strong> ir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Likums <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>p\u0101rk\u0101pj pamatties\u012bbas<\/li>\n\n\n\n<li>nav pietiekami defin\u0113ts<\/li>\n\n\n\n<li>nav demokr\u0101tiski le\u0123itim\u0113ta.<\/li>\n\n\n\n<li>nav sam\u0113r\u012bgi<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">\u012apa\u0161i svar\u012bgi ir <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Regul\u0113juma koncepcijas konsekvences tr\u016bkums<\/li>\n\n\n\n<li>Klus\u0101 papla\u0161in\u0101\u0161an\u0101s, izmantojot kombin\u0113t\u0101s vakc\u012bnas<\/li>\n\n\n\n<li>Ties\u012bbu aktu dele\u0123\u0113\u0161ana STIKO.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Eksperts argument\u0113 par labu konstit\u016bcijai atbilsto\u0161am jaunam regul\u0113jumam, kas maz\u0101k ierobe\u017eo pamatties\u012bbas un ir konsekvent\u0101ks.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Entwicklungen_seit_2019\"><\/span>Notikumi kop\u0161 2019. gada<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bundesverfassungsgericht_2022\"><\/span><strong>Feder\u0101l\u0101 konstitucion\u0101l\u0101 tiesa (2022)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">2022. gada 21. j\u016blija spriedum\u0101 Feder\u0101l\u0101 Konstitucion\u0101l\u0101 tiesa apstiprin\u0101ja, ka pras\u012bba vakcin\u0113ties pret masal\u0101m ir konstitucion\u0101la, un noraid\u012bja \u010detras pras\u012bbas, ko iesniegu\u0161as skart\u0101s \u0123imenes. Karlsr\u016bes tiesne\u0161i uzskat\u012bja, ka iejauk\u0161an\u0101s pamatties\u012bb\u0101s ir sapr\u0101t\u012bga un t\u0101d\u0113j\u0101di pamatota.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Das_Kombinationsimpfstoff-Problem_wurde_Realitat\"><\/span><strong>Kombin\u0113to vakc\u012bnu probl\u0113ma ir k\u013cuvusi par realit\u0101ti<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Vakc\u012bna pret masal\u0101m \u201eMeasles Vaccine Live\u201c vairs nav pieejama, izplat\u012bt\u0101js ir atgriezis licenci. Tas noz\u012bm\u0113, ka p\u0113d\u0113j\u0101 atsevi\u0161\u0137\u0101 masalu vakc\u012bna Eirop\u0101 vairs neb\u016bs pieejama, un vec\u0101kiem vairs neb\u016bs alternat\u012bvas de facto oblig\u0101tajai vakcin\u0101cijai ar kombin\u0113taj\u0101m vakc\u012bn\u0101m (MMR\/MMRV). . <em>\u0100rsti individu\u0101liem l\u0113mumiem par vakcin\u0101ciju e. V.<\/em> sav\u0101 inform\u0101cijas lap\u0101 ir public\u0113jusi \u0161\u0101du inform\u0101ciju. <a href=\"https:\/\/individuelle-impfentscheidung.de\/aktuelles\/masern-impfpflicht.html\" target=\"_blank\" rel=\"noreferrer noopener\">Masalas un difterija: k\u0101 parasti vakc\u012bnu autoriz\u0101cijas p\u0113t\u012bjumos, nav kl\u012bnisku pier\u0101d\u012bjumu par efektivit\u0101ti.<\/a> tematiz\u0113ts.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tie\u0161i to Rixen kritiz\u0113ja k\u0101 sl\u0113ptu, neierobe\u017eotu oblig\u0101t\u0101s vakcin\u0101cijas papla\u0161in\u0101\u0161anu.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"RKI-Bilanz_nach_5_Jahren_2025\"><\/span><strong>RKI bilance p\u0113c 5 gadiem (2025. gad\u0101)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">P\u0113c pieciem oblig\u0101t\u0101s vakcin\u0101cijas pret masal\u0101m gadiem rezult\u0101ti ir da\u017e\u0101di: vakcin\u0101cijas r\u0101d\u012bt\u0101ji ir palielin\u0101ju\u0161ies, ta\u010du, neraugoties uz vakcin\u0101cijas l\u012bme\u0146a paaugstin\u0101\u0161anos, V\u0101cij\u0101 p\u0113rn iev\u0113rojami palielin\u0101j\u0101s saslimst\u012bba ar masal\u0101m - vair\u0101k nek\u0101 560 saslim\u0161anas gad\u012bjumu. <a href=\"https:\/\/www.gelbe-liste.de\/immunologie\/masernimpfpflicht-erfolg-bewertung\" target=\"_blank\" rel=\"noreferrer noopener\">Piecus gadus ilg\u0101 oblig\u0101t\u0101 imuniz\u0101cija pret masal\u0101m: kritisks p\u0101rskats.<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Saska\u0146\u0101 ar Dzelten\u0101 saraksta virsrakstu divreiz vakcin\u0113to b\u0113rnu vakcin\u0101cijas l\u012bmenis 24 m\u0113ne\u0161u vecum\u0101 pieauga no 70 % (2019. gad\u0101) l\u012bdz 77 % (2023. gad\u0101), bet se\u0161gad\u012bgo b\u0113rnu - l\u012bdz 92 % (2023. gad\u0101). <a href=\"https:\/\/www.gelbe-liste.de\/immunologie\/masernimpfpflicht-erfolg-bewertung\" target=\"_blank\" rel=\"noreferrer noopener\">Pieci gadi oblig\u0101t\u0101s vakcin\u0101cijas pret masal\u0101m: da\u013c\u0113js pan\u0101kums sabiedr\u012bbas vesel\u012bbas aizsardz\u012bb\u0101<\/a>. Tom\u0113r PVO 95% z\u012bme netika sasniegta.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Kritische_Nebeneffekte\"><\/span><strong>Kritisk\u0101s blakuspar\u0101d\u012bbas<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Anal\u012bze atkl\u0101ja ar\u012b soci\u0101lo nevienl\u012bdz\u012bbu: Tiem, kam ir zem\u0101ks izgl\u012bt\u012bbas vai ien\u0101kumu l\u012bmenis, bie\u017ei vien bija maz\u0101k zin\u0101\u0161anu par oblig\u0101to imuniz\u0101ciju un liel\u0101ks stresa l\u012bmenis sankciju d\u0113\u013c. Aptuveni 10-12 % vec\u0101ku pauda dusmas par \u0161o pien\u0101kumu un da\u017eos gad\u012bjumos atteic\u0101s ar\u012b no cit\u0101m vakcin\u0101cij\u0101m.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Ausgeloster_Status\"><\/span><strong>Aktiviz\u0113ts statuss<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Feder\u0101l\u0101 Konstitucion\u0101l\u0101 tiesa koment\u0113ja vienu deta\u013cu: Infekciju aizsardz\u012bbas likums pie\u013cauj tikai t\u0101das kombin\u0101cijas, k\u0101das ir ierastas \u0161obr\u012bd, t.i., ar c\u016bci\u0146\u0101m, masali\u0146\u0101m un v\u0113jbak\u0101m, bet ne ar cit\u0101m papildu slim\u012bb\u0101m. Tiesne\u0161i uzskata, ka kombin\u0113t\u0101s vakcin\u0101cijas ir \u201eb\u016btiski labv\u0113l\u012bgas b\u0113rniem\u201c, jo t\u0101s iesaka STIKO, k\u0101 to var izlas\u012bt <a href=\"https:\/\/www.haufe.de\/oeffentlicher-dienst\/personal-tarifrecht\/verlaengerung-der-frist-zum-nachweis-des-masernschutzes_144_538416.html\" target=\"_blank\" rel=\"noreferrer noopener\">Feder\u0101l\u0101 konstitucion\u0101l\u0101 tiesa apstiprina oblig\u0101to vakcin\u0101ciju pret masal\u0101m dienas apr\u016bpes centru b\u0113rniem<\/a>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Fazit-2\"><\/span><strong>F<\/strong>az\u012bts<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>BVerfG ir apstiprin\u0101jusi oblig\u0101to vakcin\u0101ciju.<\/strong>, bet Prof. Dr. Stephan Rixen bija taisn\u012bba par kombin\u0113to vakc\u012bnu probl\u0113mu: viena vakc\u012bna patie\u0161\u0101m ir izzudusi. Praktisk\u0101 efektivit\u0101te ir ierobe\u017eota (m\u0113r\u0137a r\u0101d\u012bt\u0101ji nav sasniegti, bet vakcin\u0101cijas r\u0101d\u012bt\u0101ji ir palielin\u0101ju\u0161ies).<\/p>","protected":false},"excerpt":{"rendered":"<p><span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Las\u012b\u0161anas laiks<\/span> <span class=\"rt-time\"> 21<\/span> <span class=\"rt-label rt-postfix\">protokols<\/span><\/span>Bevor wir uns dem Masernschutzgesetz im Rahmen des Infektionsschutzgesetzes (IfSG) widmen, zun\u00e4chst eine wissenschaftliche Erl\u00e4uterung der Masern-Virus-Immunologie. Was sind Masern? &#8211; Spezifische Evasionsmechanismen Defizit\u00e4re Interferon-Antwort und NF-\u03baB-Dependenz Der zentrale immunologische Defekt bei Masern ist grundlegend anders als die klassische virale Immunantwort: Masern-Virus-Infektion induziert keine Typ-1-Interferone, f\u00fchrt aber zur Produktion von Zytokinen und Chemokinen, die mit&hellip;&nbsp;<a href=\"https:\/\/csiag.eu\/lv\/blog\/2026\/02\/22\/masernschutzgesetz\/\" rel=\"bookmark\">Las\u012bt vair\u0101k \"<span class=\"screen-reader-text\">Masalu \u201caizsardz\u012bbas\u201c likums?<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[1078,354],"tags":[],"class_list":["post-12796","post","type-post","status-publish","format-standard","hentry","category-medizin","category-medizin-gesundheit"],"modified_by":"Achim Goerner","_links":{"self":[{"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/posts\/12796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/comments?post=12796"}],"version-history":[{"count":0,"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/posts\/12796\/revisions"}],"wp:attachment":[{"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/media?parent=12796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/categories?post=12796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csiag.eu\/lv\/wp-json\/wp\/v2\/tags?post=12796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}